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ABSTRACT 
Progress toward the total synthesis of 9-hydroxyvertine 2 is described. Our approach involves a 
Petasis borono-Mannich reaction to assemble a key intermediate A, securing the correct configuration 
at H-9 and H-10 in the final targeted molecule. Subsequent formation of the quinolizidine framework 
B allowed the synthesis of an advanced intermediate containing all but the lactone moiety of 2. Our 
unsuccessful attempts at introducing this lactone feature are also described. 











Since the discovery of seven alkaloids from the extracts of Decodon verticillatus (family 
Lythraceae) by Ferris in 1962 many other Lythraceae alkaloids have been isolated, especially from 
Heimia salicifolia, a wild flowering plant in the Lythraceae family.1-4 This plant has been used in 
traditional medicine as an antipyretic, an emetic, a laxative, a diuretic and as an anti-inflammatory 
agent.1,3,4 Several Lythraceae alkaloids were found to exhibit remarkable biological activities, 
including vertine 1 (Figure 1), first isolated by Ferris2 and more recently in 2008 by Khan and 
coworkers,5 from the leaves of H. salicifolia, who demonstrated it had anti-inflammatory and 
antimalarial activities. The latter author also established the configuration of vertine at the three 
stereogenic centres and the chiral axis (as shown in Figure 1) by X-ray diffraction analysis.5 This 
alkaloid, and others in this family, comprise a quinolizidine ring skeleton with an axially chiral 
biphenyl substituent at C-4 which forms part of a 12-membered ring lactone system. The related 
alkaloid, 9β-hydroxyvertine 2, having a -hydroxy group at the C-9 position, was also isolated in this 
study, however no information concerning its biological activity was reported. Other members of this 
alkaloid family include decinine (10-epi-13,14-dihydrovertine), lythrine (10-epi-vertine) and lyfoline 
3.2,6 A 2018 study reported the isolation on 13 new related alkaloids along with vertine, lythrine and 
lyfoline 3 (Figure 1) and three related biphenyl ether quinolizidine lactone alkaloids.7 
 
Figure 1. Structures of vertine (1), 9β-hydroxyvertine (2) and lyfoline. 
Because of their challenging ring structures and interesting biological properties, Lythraceae 
alkaloids have become attractive synthetic target molecules. Vertine 1 was first synthesised by 
Kündig and co-workers in 2010, as the racemate and then in 2012 as the (+)-enantiomer using the ring 
closing metathesis (RCM) and the Suzuki–Miyaura coupling reactions as key steps to establish the 
macrocyclic ring (by formation of the C-13–C-14 (Z)-olefinic bond) and the biaryl axis (forming the 
C-1'–C-1" bond), respectively.8,9 In 2015, She and co-workers reported the synthesis of the related 
alkaloid dihydrolyfoline (13,14-dihydro-3), using a hydrolase-catalyzed Mannich reaction to form the 
quinolizidine ring and a biogenetic, enzymatic oxidative intramolecular coupling reaction of phenols 
to construct the macrocyclic ring and the biphenyl axis.10 Much earlier approach to these types of 
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structures, using non-enzymatic oxidative coupling methods, proved unsuccessful.11,12 However, Yang 
and coworkers reported the successful synthesis of decinine using a VOF3-mediated intramolecular 
oxidative coupling reaction of aryl ethers.13 To date the total synthesis of 9β-hydroxyvertine 2 has not 
been reported. Therefore, this challenging new quinolizidine core structure led us to investigate its 
synthesis. 
2. Results and discussion 
Our retrosynthetic analysis of 2 is shown in Scheme 1a. We envisioned that 2 could be synthesized by 
a sequence that included an intramolecular lactonization procedure from the dienyl acid 4. For 
example, via the intramolecular bromolactonization reaction of acid 4 followed by reductive removal 
of the bromine substituent from bromo lactone C (Scheme 1a).14 Alternatively, 2 could conceivably 
be obtained by a regioselective hydration (via hydroboration or oxymercuration) of the olefinic 
moiety of the quinolizidine 4 followed by a lactonization reaction of the possible C-2 secondary 
alcohol products D or E via a Yamaguchi15 (with retention at C-2) or via a Mitsunobu16 reaction (with 
inversion at C-2), respectively (Scheme 1b). Such an approach to this lactone ring system has not 
been reported, however an inspection of molecular models suggested it should be feasible with the 
desired, of the two interconverting biaryl rotamers (or atopisomers) predicted to cyclize more rapidly. 
This is also consistent with the findings of Kündig et al. using related compounds in their synthesis of 
vertine.9 Indeed, such biaryls having only two relatively small ortho-substituents are expected to have 
a relatively low barrier to rotation and thus best considered as rotamers rather than atropisomers,17 
Compound 4 could be obtained from the O-mesylation-cyclisation reaction18 of alcohol 5 (Scheme 1a) 
followed by the RCM reaction and subsequent functional group interconversion reactions of the cyano 
substituent, respectively. We envisioned a Petasis borono-Mannich (PBM) reaction18 of chiral 
substrates 6 and 7 and β-styrenylboronic acid as a key step in our synthetic plan to construct the anti-
amino alcohol moiety in compound 5. The chiral α-hydroxyaldehyde 6 could be prepared from 
commercially available pent-4-en-1-ol. The chiral primary amine 7 could be derived from the biaryl 










Scheme 1. Retrosynthetic analysis for the synthesis of compound 2. 
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First, we investigated the synthesis of the chiral amine 7 (Scheme 2). The synthesis began 
with the preparation of the boronate ester 9 from 6-bromoveratraldehyde (prepared by bromination of 
commercially available veratraldehyde19) following Castle’s procedure20 using Pd(OAc)2, 
bis(pinacolato)diboron and KOAc.  
 





Figure 2. ORTEP plot of 12 which crystalized as the (aR) configured isomer (CCDC 1898245) 
This reaction unexpectedly provided a separable mixture (3.3:1.2:1) of dehalogenated starting 
material, the homocoupling product of the aryl bromide and the desired product 9. Next, we examined 
Miyaura’s reaction conditions21 using Pd(dppf)Cl2·CH2Cl2 as a catalyst which afford the desired 
boronate ester 9 in 93% yield. Employing the Suzuki–Miyaura cross-coupling reaction conditions of 
Chausset-Boissarie9 on the aryl iodide analogue of aryl bromide 822 with 9 gave biphenyl aldehyde 10 
in only 24% yield, using 10 mol% Pd(Ph3P)4 at 95 oC for 48 h. Increasing the catalyst loading to 15 
mol % gave 10 in 88% yield while using bromide 8 and 15 mol% Pd(Ph3P)4 at 95 oC for 48 h gave 10 
in the highest yield of 94%.. The resulting aldehyde 10 was treated with (R)-N-tert-butanesulfinamide 
in the presence of KHSO423 to provide the corresponding N-sulfinyl imine 11 as a 52:48 mixture of 
biphenyl axis rotamers. A diastereoselective Zn-mediated allylation reaction of imine 11 with allyl 
bromide, Zn powder and Zn(OTf)224 provided chiral homoallyic N-sulfinyl amine 12 in 87% yield as a 
single diastereomer and as a 62:38 mixture of rotamers. Allyl bromide/Zn, in the absence of Zn(OTf)2, 
or the use of allylmagnesium bromide, gave much less satisfactory yields of 12, 74% and 10%, 
respectively. A single crystal X-ray structural analysis confirmed the structure and configuration at 
the C-1′′ position of compound 12 (Scheme 2), which crystallized as a single diastereomer with the 
(aR)-configuration at the axis. The 1H NMR spectrum of these crystals, when dissolved in CDCl3, 
showed that this single diastereomeric form in the solid state rapidly (less than 5 min) converted to the 
original 62:38 mixture of rotamers in solution at ambient temperature. Clearly indicating that these 
were rotamers rather than atropisomers17 and these were rapidly interconvertible at room temperature. 
Heating this mixture in hexadeuterated-DMSO resulted in little change in the rotamer ratio from 1H 
NMR analysis. Deprotection of the N-sulfinyl group of 12 with TMSCl in MeOH at ambient 
temperature produced the desired chiral homoallylic amine 7 in 95% yield as a 64:36 mixture of 
rotamers (Scheme 2). 
7 
 
The equivalent of the chiral α-hydroxyaldehyde 6 was synthesized as the cyclic hemiacetal 
dimer 15a in three steps from commercially available pent-4-en-1-ol (Scheme 3). p-
Methoxybenzylation of pent-4-en-1-ol with PMBCl and DIPEA gave the PMB ether 13.25 A cross-
metathesis reaction26 of 13 with phenyl vinyl sulfone and Grubbs’ second generation catalyst provided 
(E)-vinyl sulfone 14, which underwent subsequent Sharpless asymmetric dihydroxylation (ADH)27,28 
with AD-mix-β, resulting in the cyclic hemiacetal dimer 15a of the desired -hydroxyaldehyde, 
which was used without further purification. MS analysis of the crude reaction mixture indicated 
100% consumption of 14 and 1H NMR analysis showed resonances consistent with structure 15a as a 
mixture of diastereomers. 
 
Scheme 3. Synthesis of the chiral α-hydroxyaldehyde hemiacetal dimer 15a. 
With our two chiral substrates in hand, the next task was constructing the key intermediate 
16a via the PBM reaction as shown in Scheme 4. The aldehyde dimer 15a was treated with the chiral 
amine 7 and -styrenylboronic acid in EtOH which provided a chromatographically separable mixture 
of two diastereomers, the desired anti-1,2-amino alcohol 16a (37%) and the unexpected syn-1,2-
amino alcohol 16b (35%). These were both formed as 60:40 mixtures of rotamers The configurations 
of the products 16a and 16b were confirmed by treatment of the individual diastereomers with 
triphosgene to give their respective oxazolidinone derivatives, 17a (63:37 mixture of rotamers) and 
17b (53:47 mixture of rotamers) (Scheme 4). NOESY spectrum analysis of 17a showed a key 
correlation between H-4′′′ and H-5′′′ which indicated the relative syn stereochemical relationship of 
these protons in the oxazolidinone 17a. In comparison, NOESY spectrum analysis of 17b showed no 
correlation between H-4′′′ and H-5′′′ indicating their trans-relative configuration. These results 




Scheme 4. Synthesis of 1,2-amino alcohols 16a and 16b and oxazolidinones 17a and 17b. 
To further confirm the identity of compounds 16a and 16b, we investigated the PBM reaction 
of amine 7 with the enantiomeric α-hydroxyaldehyde dimer 15b, which was prepared by an ADH 
reaction of vinyl sulfone 14 with AD-mix-α (Scheme 5). This reaction provided the anti-1,2-amino 
alcohol product 16c in 68% yield as a single diastereomer and as a 56:44 mixture of rotamers The 1H 
NMR spectrum of 16c showed clear differences in chemical shifts and splitting patterns when 
compared to those of 16a and 16b. The relative anti configuration of the product 16c was verified by 
formation of the cis-oxazolidinone 17c (67:33 mixture of rotamers) and NOE experiments (Scheme 
5). This experiment helped confirm our structural assignments to 16a and 16b and ruled out the 
possibility that the -hydroxyaldehyde 6, formed in situ from 15a, had undergone epimerization 




Scheme 5. Synthesis of 1,2-amino alcohol 16c and oxazolidinones 17c. 
To investigate the PMB reaction further the sterically less demanding homoallylic amine 20 
was prepared according to Scheme 6. In this synthesis, the allylation of the less sterically hindered N-
sulfinyl imine 18 occurred efficiently with allylmagnesium bromide in the absence of a Lewis acid 
giving 19 in 82% yield. Deprotection of the N-sulfinyl group of 19 then produced the desired chiral 
homoallylic amine 20 in 88% yield. In contrast to amine 7, the PMB reaction between the chiral 
amine 20, the aldehyde dimer 15a and -styrenylboronic acid in EtOH gave the anti-1,2-amino 









Scheme 6. Synthesis of 1,2-amino alcohol 21. 
Thus the reaction of the aldehyde dimer 15a with the chiral amine 7 represents one of the few 
examples of the PBM reaction where poor anti-diastereoselectivity has been observed.18,28 Our 
proposed reactive intermediates for the formation of the products 16a, 16b and 16c are shown in 
Scheme 7. Intermediates F and H are expected as 1,3-allylic strain between the -imine substituents 
and the imine substituents (-H and imine H “inside”) is minimized.28 However, in the case of the 
(R)-aldehyde 6 (derived from 15a), when R1 is large (R1 = biphenyl substituent) then we would expect 
to observe poor diastereoselectivity due to steric interference between R1 and R3 in intermediate F. 
Therefore reaction via the alternative intermediate G can compete giving rise to the syn-product 16b. 
When the (S)-aldehyde (ent-6) derived from 15b was used then high anti-diastereoselectivity was 
observed. In this case the R3 group is delivered anti to the bulky R1 group via the expected reactive 
conformation H to give exclusively anti-16c. 
While in principle, compound 21 could be converted to 16a via a Suzuki–Miyaura cross-
coupling reaction with boronate 9, this was not attempted because of the relative poor yield (44%) of 
21 which was similar to the yield of 16a (37% yield) from the PMB reaction of 7 and 15a (Scheme 4). 
Of note was the attempted removal of the PMB ether protecting group of 21 with DDQ, which while 
successful in the case of 16a (Scheme 8), resulted in a complex mixture of products from 1H NMR 
analysis of the crude reaction mixture. We speculate that the bromodimethoxy-substituted aromatic 
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ring of 21 may have undergone oxidation to a reactive para-quinone intermediate resulting in the 
formation of undesired products.  
 
Scheme 7. Proposed reactive intermediates for the formation of products 16a,b and 20. 
We next examined the synthesis of the quinolizidine framework 24 as shown in Scheme 8. 
All products having a biphenyl moiety in Scheme 8, and in later schemes, were formed as mixtures of 
rotamers. The ratio of these rotamers is provided in the experimental section. The deprotection of the 
PMB group of the desired alcohol 16a with DDQ29 in CH2Cl2/H2O provided the corresponding diol 
22. The use of CAN30 in this deprotection reaction resulted in a complex mixture of products. The diol 
22 was subsequently subjected to the O-mesylation-cyclization reaction conditions18 using 1 equiv of 
MsCl to give piperidine 23 in 54% yield and recovered 22 in 31% yield. The RCM reaction of diene 
23 with Grubbs’ second generation catalyst in the presence of Ti(i-PrO)4 as a Lewis acid, which was 
expected to prevent deactivation of the Ru catalyst by coordination to the N-atom,31,32 provided the 
quinolizidine 24 in 40% yield. Due to the low yield of 24 and the incomplete O-mesylation-
cyclization of diol 22, we decided to modify the original route from alcohol 16a. The secondary 
hydroxy group in compound 16a was protected as a TBS ether which would potentially allow us to 
increase the amounts of Et3N and MsCl, and hence enhance the yield, in the N-cyclization reaction 
sequence. Unfortunately, the smooth removal of the PMB group from the resulting TBS ether of 16a 
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was unsuccessful. The use of DDQ resulted in a complex mixture, while the use of CAN 
unexpectedly provided the amine 7 resulting from oxidative cleavage of the styrenyl side chain. 
 
Scheme 8. Synthesis of quinolizidine 24. 
To overcome the above issues, we decided to modify the original route from the preparation 
of the α-hydroxyaldehyde dimer by protecting the primary hydroxy group of 27 as its TBS ether. 
Silylation of commercially available pent-4-en-1-ol with TBSCl provided TBS ether 25. Treatment of 
25 under the same cross-metathesis and ADH conditions as depicted in Scheme 3 produced the 




Scheme 9. Synthesis of alcohol 28a and 28b. 
The PBM reaction of 27, amine 7 and -styrenylboronic acid provided a mixture of 
diastereomeric 1,2-amino alcohols 28a (43%) and 28b (35%), which were obtained as pure isomers 
after separation by column chromatography. The synthesis of quinolizidines 32a and 32b is illustrated 
in Scheme 10. The cyclizations of 28a and 28b to their respective piperidine derivatives required 
protection of their secondary hydroxy groups and then selective deprotection of their primary hydroxy 
groups. After the secondary hydroxy groups of 28a,b were protected as their TBS ethers, the primary 
TBS ethers of 29a,b were selectively deprotected with HF•pyridine33 in THF to provide the 
corresponding primary alcohol products 30a and 30b. The O-mesylation-cyclization reaction of 30a,b 
produced the corresponding piperidines, 31a and 31b in 88 and 86% yields, respectively. The RCM 
reaction of 31b was initially performed following the literature method,32 with the use of Ti(i-PrO)4 as 
a Lewis acid in CH2Cl2, to give the quinolizidine 32b in only 26% yield. While, changing the solvent 
to DCE, in the absence of Ti(i-PrO)4 at 80 °C, significantly improved the yield of 32b to 67%. We 
then applied the optimized RCM reaction conditions to the desired compound 31a resulting in the 
corresponding quinolizidine 32a in 70% yield. The 2D NOESY analysis of 32a showed no correlation 
between the resonances for H-1′′ and H-9a′′ which confirmed the relative anti stereochemical 
relationship of these protons in the quinolizidine ring. While the 2D NOESY spectrum of 32b showed 





Scheme 10. Synthesis of quinolizidines 32a and 32b. 
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With our key intermediates 32a and 32b in hand, we focused our investigation towards 
completion of the total synthesis of 2 (Scheme 11). Therefore, the cyano groups of the quinolizidines 
32a,b were reduced by treatment with DIBAL-H to give their corresponding aldehydes 33a and 33b. 
The ROESY spectrum of compound 33b showed a clear correlation between the resonance for H-6′′ 
and H-9a′′, consistent with their 1,3-diaxial relationship and the overall stereochemical assignments 
made to this compound and earlier related ones. These were subsequently subjected to Still–Gennari 
modified Horner-Wadsworth-Emmons (HWE) reactions9,34 to afford the methyl esters 34a and 34b, 
respectively, with complete Z-selectivities, as confirmed by the magnitude of J2,3 (12.8 Hz)9 which 
was consistent with the expected (Z)-alkene. Hydrolysis of methyl esters 34a,b with LiOH•H2O35 
provided, after acidification, the corresponding carboxylic acids in >99% conversion as confirmed by 
LRESIMS analysis of the crude reaction mixture. Attempted bromolactonization of these carboxylic 
acids using NBS in the presence of a catalytic amount of (PhSe)214,36 unexpectedly generated 
decarboxylated products, the (Z)-bromoalkenes 35a and 35b (in 18% and 14% yields over the two 
steps, respectively, bromo-alkene vicinal couplings of 8.0 Hz37). The synthesis of (Z)--
bromostryrenes from the bromination of (E)-cinnamic acids followed by treatment with base is well 
documented.37 In the case of 34a,b, the highly electron rich biphenyl substituent clearly favours 
bromination of the -unsaturated carboxylic acid moiety over that of the alkene group in the 
quinolizidine ring. The amino group of this ring may assist in the decarboxylative-elimination process 
leading to the (Z)--bromostryrene products. Other halolactonization conditions (e.g. I2, NaHCO3, 




Scheme 11. Synthesis of methyl esters 35a,b and attempted bromolactonization. 
At this point, and with only limited amounts of advanced materials in hand, we envisioned an 
alternative strategy involving regioselective hydroboration of the alkene group of the quinolizidine 
34a (Scheme 12). Unfortunately, the reaction was not successful and only starting material was 
recovered even in the presence of 8 equiv of BH3•SMe2. We suspected that a Lewis acid-base 
complex was formed between BH3 and the N-atom of 34a resulting in deactivation of the alkene, 
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electronically by the withdrawal of electron density towards the cationic N atom, and sterically by 
increased steric hindrance. 
 
Scheme 12. Attempted hydroboration of 34a. 
We also considered another possible synthetic strategy to approach the alcohol 36 via 
selective hydration of 32a followed by reduction of the cyano group to an aldehyde and subsequent Z-
selective HWE reaction to provide intermediate 36. To test this possibility, we investigated the 
oxymercuration reaction40 of 32a by reacting with Hg(NO3)2 in THF at rt, this reaction was 
surprisingly slow and required 5 d for full consumption of 32a (by TLC analysis). The reaction 
mixture was then treated with NaBH4 and NaOH solution (Scheme 13). Separation of the reaction 
products over silica gel gave the product 37, as a single diastereomer, but in only 6% yield. The 
alcohol 24, the desilylated product of 32a, was isolated in 15% yield. An analysis of the COSY NMR 
spectrum of 37 indicated that the reaction provided the product with the desired regiochemistry but 
the configuration at H-8 could not be unequivocally determined by NOESY NMR. Performing the 
reaction with other mercury salts, such as Hg(OAc)2 and Hg(OTFA)2, resulted in recovered unreacted 
staring material. 
 
Scheme 13. Oxymercuration of 32a. 
3. Conclusions 
During the course of this study, we have achieved the synthesis of the advanced quinolizidine 
intermediate 34a containing most of the structural characteristics of 9β-hydroxyvertine 2, including 
three stereogenic centres. This approach highlights the value of the PBM reaction, coupled with RCM 
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and the tandem chemoselective O-mesylation, N-cyclization strategy to prepare highly functionalized 
quinolizidines. While these methods will be of general utility to synthetic chemists, this study 
revealed a rare example of a poorly diastereoselective PBM reaction due to the use of a highly 
hindered and chiral amine component, the presence of which overrides the intrinsic bias for high anti-
diastereoselectivity in these reactions. Future efforts will be directed towards alternative strategies for 
completing the synthesis of 2. 
4. Experimental section 
4.1 General information 
All air and moisture sensitive reactions were conducted under an atmosphere of dry argon or 
nitrogen using oven-fried or flame-dried glassware in anhydrous solvents. Flash column 
chromatography was performed on 230-400 mesh silica gel. Reaction products were detected on thin 
layer chromatography by UV light or by staining with ceric ammonium molybdate solution. 1H NMR 
(500 MHz) and 13C NMR (125 MHz) spectra were recorded on Varian Unity Inova or Bruker 
AVANCE 500 MHz spectrometer in deuterochloroform (CDCl3) solution. Chemical shifts are 
reported in ppm (δ) relative to a residual solvent peak (CDCl3 = 7.26 ppm for 1H and 77.16 ppm for 
13C) or tetramethylsilane (TMS). Coupling constants (J) are reported in Hertz (Hz). NMR assignments 
are based on COSY, HSQC, HMBC, and in some cases NOESY, NMR experiments. IR spectra were 
determined on neat samples on SHIMADZU MIRacle 10 IRAffinity 1 FT-IR spectrometer. Optical 
rotations were recorded on a JASCO 2000 series polarimeter. Low resolution mass spectra (LRMS) 
and high resolution mass spectra (HRMS) were recorded on a single quadrupole mass spectrometer 
and a quadrupole time-of-flight mass spectrometer, respectively, using an electrospray ionization 
(ESI) source in either the positive or negative modes. Melting points were obtained using a 
Gallenkamp MF-370 capillary tube melting point apparatus. PS refers to petroleum spirit, bp 40-60 
oC. 
4.2 Synthesis of 4-(Benzyloxy)-3-bromobenzonitrile (8)22  
To a solution of 4-hydroxy-3-bromobenzonitrile (2.43 g, 12.3 mmol, 1.0 equiv) in acetone (25 
mL) was added potassium carbonate (5.09 g, 36.8 mmol, 3.0 equiv) and benzyl bromide (2.31 g, 1.6 
mL, 13.5 mmol, 1.07 equiv) and the mixture was stirred at reflux for 20 h. After cooling to room 
temperature, the solvent was filtered and evaporated and redissolved in EtOAc (10 mL) followed by 
washing with water (2 x 10 mL). The combined organic layer was dried (MgSO4) and concentrated in 
vacuo. The crude product was purified by recrystallization from CH2Cl2 to afford the title compound 8 
as a pale yellow solid (3.34 g, 95%). The spectroscopic data of this compound matched with those in 
the literature.18 Rf = 0.27 (EtOAc:PS = 15:85). mp: 98-100 °C. IR (neat): νmax 3062, 2224, 1595, 1492, 
1452, 1381, 1258, 998, 812, 737, 695 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.84 (d, J = 2.1 Hz, 1H, H-
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2), 7.54 (dd, J = 8.6, 2.1 Hz, 1H, H-6), 7.47 – 7.32 (m, 5H, ArH), 6.97 (d, J = 8.6 Hz, 1H, H-5), 5.22 
(s, 2H, PhCH2O). 13C NMR (125 MHz, CDCl3): δ 158.6 (C-4), 136.9 (C-2), 135.3 (ArC), 133.1 (C-6), 
128.9 (2 x ArCH), 128.5 ArCH), 127.1 (2 x ArCH), 117.8 (C≡N), 113.5 (C-5), 113.0 (C-3), 105.6 (C-
1), 71.1 (PhCH2O). 
4.3 Synthesis of 4,5-Dimethoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (9)20  
To a solution of bis(pinacolato)diboron (1.68 g, 6.6 mmol, 1.1 equiv) and [1,1′-
bis(diphenylphos-phino)ferrocene]dichloropalladium(II), complex with dichloromethane (0.417 g, 
0.18 mmol, 0.03 equiv) in anhydrous THF (19 mL) was added potassium acetate (1.77 g, 18.0 mmol, 
3.0 equiv) and 2-bromo-4,5-dimethoxy-benzaldehyde19 (1.47 g, 6.0 mmol, 1.0 equiv) and the mixture 
was stirred and heated at 55 °C for 18 h. After cooling to room temperature, the reaction mixture was 
poured into ice water and extracted with EtOAc (2 x 30 mL). The combined organic layer was washed 
with brine, dried (MgSO4) and concentrated in vacuo. The crude product was purified by column 
chromatography (20:80 EtOAc/hexanes) to afford the title compound 9 as a white solid (1.62 g, 93%). 
The spectroscopic data of this compound matched with those in the literature.24 Rf = 0.47 
(EtOAc:hexanes = 30:70). mp: 98-100 °C. IR (neat): νmax 3015, 2980, 1680, 1583, 1517, 1299, 1153, 
1035, 877, 734 cm-1. 1H NMR (500 MHz, CDCl3): δ 10.59 (s, 1H, CHO), 7.55 (s, 1H, H-6), 7.35 (s, 
1H, H-3), 4.01 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 1.38 (s, 12H, 4 x CH3). 13C NMR (125 MHz, 
CDCl3): δ 193.7 (C=O), 152.9 (C-4), 151.4 (C-4), 136.5 (C-1 and C-2), 117.4 (C-3), 108.8 (C-6), 84.4 
(OC(CH3)2), 56.2 (OCH3), 56.1 (OCH3), 25.0 (4 x CH3). 
4.4 Synthesis of 6-(Benzyloxy)-2'-formyl-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (10) 
To a solution of aldehyde 8 (0.144 g, 0.5 mmol, 1.0 equiv) in degassed anhydrous 1,2-
dimethoxyethane (5 mL) was added boronate ester 9 (0.219 g, 0.75 mmol, 1.5 equiv),  cesium fluoride  
(0.228 g, 1.5 mmol, 3.0 equiv) and Pd(PPh3)4 (0.087 g, 0.075 mmol, 0.15 equiv) and the mixture was 
stirred and heated at reflux for 48 h. After cooling to room temperature, the reaction mixture was 
filtered through a short pad of celite and the residue was washed with EtOAc. The organic layer was 
dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography 
(10:20:70 EtOAc/CH2Cl2/hexanes) to afford the title compound 10 as a white solid (0.175 g, 94%). Rf 
= 0.18 (EtOAc:hexanes = 20:80). mp: 132-134 °C. IR (neat): νmax 3008, 2936, 2225, 1677, 1595, 
1511, 1346, 1251, 1154, 989, 728 cm-1. 1H NMR (500 MHz, CDCl3): δ 9.66 (s, 1H, CHO), 7.68 (dd, J 
= 8.6, 2.1 Hz, 1H, H-4), 7.58 (d, J = 2.1 Hz, 1H, H-2), 7.51 (s, 1H, H-3′), 7.35 – 7.24 (m, 3H, ArH), 
7.19 (d, J = 7.1 Hz, 2H, ArH), 7.10 (d, J = 8.6 Hz, 1H, H-5), 6.75 (s, 1H, H-6′), 5.16 – 5.06 (m, 2H, 
PhCH2O), 3.98 (s, 6H, OCH3), 3.94 (s, 6H, OCH3). 13C NMR (125 MHz, CDCl3): δ 190.4 (C=O), 
159.4 (C-6), 153.8 (C-5′), 149.3 (C-4′), 135.4 (C-2), 135.4 (ArC), 134.4 (C-1′), 134.3 (C-4), 128.9 (C-
1 and 2 x ArCH), 128.5 (ArCH), 127.4 (C-2′), 127.1 (2 x ArCH), 118.7 (C≡N), 113.1 (C-6′), 113.1 
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(C-5), 108.8 (C-3′), 104.8 (C-3), 70.9 (PhCH2O), 56.4 (OCH3), 56.3 (OCH3). HRMS (ESI): m/z calcd 
for C23H19NO4Na [M + Na]+: 396.1212, found: 396.1197. 
4.5 Synthesis of (R)-N-((2'-(Benzyloxy)-5'-cyano-4,5-dimethoxy-[1,1'-biphenyl]-2-yl)methylene)-2-
methylpropane-2-sulfinamide (11) 
To a solution of carbonitrile 10 (0.471 g, 1.26 mmol) in CH2Cl2 (3 mL) was added potassium 
hydrogen sulfate (1.722 g, 12.6 mmol, 10.0 equiv) and (R)-(+)-2-methyl-2-propanesulfinamide (0.234 
g, 1.89 mmol, 1.5 equiv) and the mixture was stirred at room temperature for 24 h. The reaction 
mixture was filtered through a short pad of celite and concentrated in vacuo. The crude product was 
purified by column chromatography (25:75 EtOAc/hexanes) to afford the title compound 11 as a 
white powder (0.537 g, 89%). 1H NMR analysis revealed the presence of two biphenyl axis rotamers 
in a 52:48 ratio. Rf = 0.42 (EtOAc:hexanes = 30:70). IR (neat): νmax 2962, 2222, 1601, 1582, 1510, 
1453, 1212, 1156, 1075, 697 cm-1. [𝛼]𝐷
25 - 41 (c 0.25, CHCl3). 1H NMR (500 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 8.27 (s, 1H, N=CH), 7.69 – 7.59 (m, 2H, H-3 and 
H-4′), 7.51 (s, 1H, H-6′), 7.33 – 7.23 (m, 3H, ArH), 7.19 (d, J = 7.3 Hz, 1.04H, ArH), 7.15* (d, J = 
7.1 Hz, 0.96H, ArH), 7.08 (d, J = 8.6 Hz, 0.52H, H-3′), 7.04* (d, J = 8.7 Hz, 0.48H, H-3′), 6.75 (s, 
1H, H-6), 5.16 – 5.07 (m, 2H, PhCH2O), 4.00* (s, 1.44H, OCH3), 3.98 (s, 1.56H, OCH3), 3.94* (s, 
1.44H, OCH3), 3.92 (s, 1.56H, OCH3), 1.21 (s, 4.68H, CH3), 1.11* (s, 4.32H, CH3). 13C NMR (125 
MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 161.0 (N=CH), 159.31 (C-2′), 
159.28* (C-2′), 152.3 (C-5), 149.2 (C-4), 149.1* (C-4), 135.8* (ArC), 135.6 (C-6′), 135.5 (ArC), 
135.2* (C-6′), 134.2 (C-4′), 134.1* (C-4′), 132.8 (C-1), 130.0* (C-1′), 129.4 (C-1′), 128.8 (1 x ArCH), 
128.7* (0.9 x ArCH), 128.3 (0.6 x ArCH), 128.0* (0.4 x ArCH), 127.0 (1 x ArCH), 126.4* (0.9 x 
ArCH), 125.4 (C-2), 118.9 (C≡N), 113.3 (C-3′), 113.19* (C-6), 113.16 (C-6), 109.9* (C-3), 109.2 (C-
3), 104.8 (C-5′), 104.7* (C-5′), 70.8 (PhCH2O), 70.5* (PhCH2O), 57.8 ((CH3)3C), 57.5* ((CH3)3C), 
56.3*(OCH3), 56.1 (OCH3), 22.7 ((CH3)3C), 22.5* ((CH3)3C). HRMS (ESI): m/z calcd for 
C27H28N2O4NaS [M+Na]+: 499.1667, found: 499.1674. 
4.6 Synthesis of (R)-N-((S)-1-(2'-(Benzyloxy)-5'-cyano-4,5-dimethoxy-[1,1'-biphenyl]-2-yl)but-3-en-1-
yl)-2-methylpropane-2-sulfinamide (12) 
To a solution of the N-sulfinyl imine 11 (0.726 g, 1.52 mmol, 1.0 equiv) in anhydrous THF 
(5.0 mL) was added zinc powder (0.299 g, 4.57 mmol, 3.0 equiv), zinc trifluoromethanesulfonate 
(1.70 g, 4.57 mmol, 3.0 equiv) and allyl bromide (0.576 g, 0.42 ml, 4.87 mmol, 3.2 equiv) and the 
mixture was stirred at room temperature for 8 h. After the reaction had completed, the mixture was 
quenched with sat. aqueous NH4Cl solution and extracted with EtOAc (2 x 10 mL). The organic layer 
was washed with brine, dried (MgSO4) and concentrated in vacuo. The crude product was purified by 
column chromatography (50:50 EtOAc/hexanes) to afford the title compound 12 as a pale yellow 
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crystalline solid (0.684 g, 87%). 1H NMR analysis revealed the presence of two biphenyl axis 
rotamers in a 62:38 ratio. Rf = 0.21 (EtOAc:hexanes = 60:40). mp: 156-158 °C. IR (neat): νmax 3271, 
2936, 2225, 1662, 1512, 1495, 1155, 1030, 747 cm-1. [𝛼]𝐷
25  - 89 (c 0.20, CHCl3). 1H NMR (500 MHz, 
the asterisk* denotes the signal of the the minor rotamer, CDCl3): δ 7.64 – 7.57 (m, 1.38H, H-4′ and 
H-6′ (minor)), 7.42 (s, 0.62H, H-6′), 7.31 – 7.15 (m, 5H, ArH), 7.03 (s, 1H, H-3′), 7.01 (s, 0.62 H, H-
3), 6.93* (s, 0.38 H, H-3), 6.66 (s, 0.62H, H-6), 6.63* (s, 0.38H, H-6), 5.61 – 5.45 (m, 1H, H-3′′), 5.34 
(d, J = 13.1 Hz, 0.62H, PhCHAHBO), 5.19 (d, J = 13.0 Hz, 0.62H, PhCHAHBO), 5.15 – 4.96 (m, 
2.76H, H-4′′ and PhCH2O (minor)), 4.23 (dd, J = 8.6, 5.3 Hz, 0.62H, H-1′′), 4.21* – 4.17* (m, 0.38H, 
H-1′′), 3.90 (s, 3H, OCH3), 3.88 (s, 1.86H, OCH3), 3.85 (s, 1.14H, OCH3), 3.54* (s, 0.38H, NH), 3.48 
(s, 0.62H, NH), 2.49* (m, 0.38H, H-2′′), 2.43 – 2.20 (m, 1.62H, H-2′′), 1.17* (s, 3.42H, CH3), 1.07 (s, 
5.58H, CH3). 13C NMR (125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 
159.5* (C-2′), 159.4 (C-2′), 149.1* (C-4), 149.0 (C-4), 148.0 (C-5), 147.97* (C-5), 136.5 (ArC), 
135.8* (ArC), 135.7* (C-6′), 135.4 (C-6′), 134.7* (C-3′′), 134.2 (C-3′′), 133.8* (C-4′), 133.7 (C-4′), 
132.9 (C-2), 132.1* (C-2), 131.1* (C-1′), 131.0 (C-1′), 128.8 (0.76 x ArCH), 128.7* (C-1), 128.5 
(1.24 x ArCH), 128.3 (C-1), 128.26* (0.38 x ArCH), 127.7 (0.62 x ArCH), 126.8* (0.76 x ArCH), 
126.5 (1.24 x ArCH), 119.5 (C-4′′), 119.2 (C≡N), 119.0* (C≡N), 118.8* (C-4′′), 113.3 (C-3′), 
112.9*(C-6), 112.8* (C-3′), 112.79 (C-6), 109.7 (C-3), 104.8* (C-5′), 103.7 (C-5′), 70.4* (PhCH2O), 
70.3 (PhCH2O), 56.1 (OCH3), 56.0* (OCH3), 55.99* (OCH3), 55.95 (OCH3), 55.7* (C(CH3)3), 55.4 
(C(CH3)3), 53.6* (C-1′′), 53.0 (C-1′′), 43.5 (C-2′′), 42.6* (C-2′′), 22.7* (C(CH3)3), 22.8 (C(CH3)3). 
HRMS (ESI): m/z calcd for C30H34N2O4NaS [M+Na]+: 541.2137, found: 514.2135. 
4.7 Synthesis of (S)-2'-(1-Aminobut-3-en-1-yl)-6-(benzyloxy)-4',5'-dimethoxy [1,1'-biphenyl]-3-
carbonitrile (7) 
To a solution of sulfinamide 12 (0.220 g, 0.42 mmol, 1.0 equiv) in MeOH (2.5 mL) was 
added TMSCl (0.092 g, 0.85 mmol, 2.0 equiv) and the solution was stirred at room temperature for 30 
min. The solution was then evaporated to dryness in vacuo and the residue was washed with Et2O (5 
mL) and redissolved in CH2Cl2 (2 mL). The solution was washed with sat. aqueous NaHCO3 solution. 
The organic layer was dried (MgSO4) and concentrated in vacuo to afford the title compound 7 as a 
pale yellow oil (0.167 g, 95%) which was used in the next step without further purification. 1H NMR 
analysis revealed the presence of two biphenyl axis rotamers in a 64:36 ratio. Rf = 0.21 
(MeOH:CH2Cl2 = 5:95). IR (neat): νmax 3420, 3365, 3072, 2917, 2224, 1599, 1490, 1247, 1154, 734, 
695 cm-1. 1H NMR (500 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.64 – 
7.59 (m, 1H, H-4), 7.49* (s, 0.36H, H-2), 7.46 (s, 0.64H, H-2), 7.30 (d, J = 7.2 Hz, 3H, ArH), 7.18 (d, 
J = 7.0 Hz, 2H, ArH), 7.12 – 7.02 (m, 2H, H-5 and H-3′), 6.62* (s, 0.36H, H-6′), 6.57 (s, 0.64H, H-
6′), 5.61 – 5.42 (m, 1H, H-3′′), 5.17 – 5.07 (m, 2H, PhCH2O), 5.02 – 4.90 (m, 2H, H-4′′), 3.96 (s, 3H, 
OCH3), 3.87 (s, 1.92H, OCH3), 3.84 (s, 1.08H, OCH3), 3.78 – 3.70 (m, 1H, H-1′′), 2.34* – 2.26* (m, 
0.36H, H-2′′), 2.25 – 2.16 (m, 1.64H, H-2′′), 1.45 (br s, 2H, NH2). 13C NMR (125 MHz, the asterisk* 
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denotes the signal of the minor rotamer, CDCl3): δ 159.7* (C-6), 159.2 (C-6), 149.3 (C-4′), 149.2* (C-
4′), 147.6 (C-5′), 147.4* (C-5′), 136.9 (C-2′), 136.5* (C-2′), 135.8* (C-2), 135.7 (ArC), 135.6 (C-2), 
135.3 (C-3′′), 135.2* (C-3′′), 133.5* (C-4), 133.3 (C-4), 132.3 (C-1), 131.9* (C-1), 128.9 (1.28 x 
ArCH), 128.8* (0.72 x ArCH), 128.5 (0.64 x ArCH), 128.2* (0.36 x ArCH), 127.1* (C-1′), 127.0 
(1.28 x ArCH), 126.9 (C-1′), 126.7* (0.72 x ArCH), 119.2 (C≡N), 117.6 (C-4′′), 117.4* (C-4′′), 
113.0* (C-5), 112.9 (C-5 and C-6′ (minor)), 112.6 (C-6′), 108.8* (C-3′), 108.6 (C-3′), 104.5 (C-3), 
104.2* (C-3), 70.6 (PhCH2O), 70.4* (PhCH2O), 56.2 (OCH3), 56.1* (OCH3), 56.09* (OCH3), 56.07 
(OCH3), 51.8 (C-1′′), 51.2* (C-1′′), 43.7 (C-2′′), 43.2* (C-2′′). HRMS (ESI): m/z calcd for C26H27N2O3 
[M + H]+: 415.2012, found: 415.2019. 
4.8 Synthesis of 1-Methoxy-4-((pent-4-en-1-yloxy)methyl)benzene (13)25  
To a solution of 4-penten-1-ol (1.03 g, 12.0 mmol, 1.0 equiv) was added DIPEA (2.019 g, 2.7 
mL, 15.6 mmol, 1.3 equiv) and PMBCl (2.05 g, 1.8 mL, 13.1 mmol, 1.1 equiv) and stirred at 150 °C 
for 2 h. After the reaction had completed, EtOAc (60 mL) was added and washed with 10% NaHSO4 
(60 mL). The aqueous layer was washed with EtOAc (2 x 60 mL). The combined organic layer was 
dried and concentrated in vacuo. The crude product was purified by column chromatography on silica 
gel eluting with 5:95 EtOAc/hexanes to afford the title compound 13 as a colorless oil (2.378 g, 96%). 
The spectroscopic data of this compound matched with those in the literature.21 Rf = 0.40 
(EtOAc:hexanes = 5:95). IR (neat): νmax 3078, 2937, 2854, 1613, 1511, 1245, 1097, 1035, 819 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.26 (d, J = 8.5 Hz, 2H, ArH), 6.88 (d, J = 8.5 Hz, 2H, ArH), 5.81 
(ddt, J = 17.0, 10.1, 6.7 Hz, 1H, H-4), 5.01 (dd, J = 17.0, 1.8 Hz, 1H, H-5A), 4.95 (d, J = 10.1 Hz, 1H, 
H-5B), 4.43 (s, 2H, PMPCH2O), 3.80 (s, 3H, OCH3), 3.45 (t, J = 6.5 Hz, 2H, H-1), 2.18 – 2.09 (m, 2H, 
H-3), 1.75 – 1.65 (m, 2H, H-2). 13C NMR (125 MHz, CDCl3): δ 159.2 (ArC), 138.4 (C-4), 130.8 
(ArC), 129.3 (2 x ArCH), 114.8 (C-5), 113.8 (2 x ArCH), 72.6 (PMPCH2O), 69.5 (C-1), 55.3 (OCH3), 
30.5 (C-3), 29.1 (C-2). 
4.9 General Method for Olefin Cross Metathesis 
4.9.1 Synthesis of (E)-1-Methoxy-4-(((5-(phenylsulfonyl)pent-4-en-1-yl)oxy)methyl)benzene (14) 
To a solution of alkene 13 (0.516 g, 2.5 mmol, 1.0 equiv) in degassed anhydrous CH2Cl2 (9 
mL) was added phenyl vinyl sulfone (1.26 g, 7.5 mmol, 3.0 equiv) and Grubbs’ II ruthenium catalyst 
(0.106 g, 0.125 mmol, 0.05 equiv) and the mixture was stirred and heated at reflux for 18 h. The 
reaction mixture was cooled to room temperature and the solvent was evaporated. The crude product 
was purified by column chromatography on silica gel eluting with 10:25:65 Et2O/CH2Cl2/hexanes to 
afford the title compound 14 as a colorless oil (0.654 g, 76%). Rf = 0.62 (EtOAc:hexanes = 40:60). IR 
(neat): νmax 3060, 2861, 1612, 1511, 1447, 1305, 1245, 1144, 1032, 816, 752 cm-1. 1H NMR (500 
MHz, CDCl3): δ 7.86 (d, J = 7.7 Hz, 2H, ArH), 7.61 (t, J = 7.5 Hz, 1H, ArH), 7.53 (t, J = 7.7 Hz, 2H, 
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ArH), 7.22 (d, J = 8.6 Hz, 2H, ArH), 6.99 (dt, J = 15.0, 6.8 Hz, 1H, H-4), 6.87 (d, J = 8.6 Hz, 2H, 
ArH), 6.30 (d, J = 15.0 Hz, 1H, H-5), 4.38 (s, 2H, PMPCH2O), 3.80 (s, 3H, OCH3), 3.43 (t, J = 6.1 
Hz, 2H, H-1), 2.39 – 2.27 (m, 2H, H-3), 1.75 (p, J = 6.6 Hz, 2H, H-2). 13C NMR (125 MHz, CDCl3): 
δ 159.4 (ArC), 146.7 (C-4), 140.9 (ArC), 133.3 (ArCH), 130.9 (C-5), 130.4 (ArC), 129.4 (2 x ArCH), 
129.3 (2 x ArCH), 127.7 (2 x ArCH), 114.0 (2 x ArCH), 72.8 (PMPCH2O), 68.7 (C-1), 55.4 (OCH3), 
28.5 (C-3), 28.0 (C-2). HRMS (ESI): m/z calcd for C19H22O4NaS [M + Na]+: 369.1131, found: 
369.1135. 
4.10 General Method for Sharpless Asymmetric Dihydroxylation (ADH) 
4.10.1 Synthesis of (3R,6R)-3,6-Bis(3-((4-methoxybenzyl)oxy)propyl)-1,4-dioxane-2,5-diol (15a).  
To a solution of phenylvinylsulfone (0.173 g, 0.5 mmol, 1.0 equiv) in 1:1 t-BuOH/water (5 
mL) was added methanesulfonamide (0.105 g, 1.1 mmol, 2.2 equiv) and AD-mix-β (3.50 g) and the 
mixture was stirred at room temperature for 24 h. The reaction mixture was quenched with sat. 
aqueous NaSO3 solution and extracted with EtOAc (2 x 10 mL). The combined organic layer was 
wash with brine, dried (MgSO4) and concentrated in vacuo to afford a crude Sharpless ADH product 
as a brown oil which was used without further purification. HRMS (ESI): m/z calcd for C13H19O4 [M 
+ H]+: 239.1283, found: 239.1286. 
4.11 General Method for the PBM Reaction with α-Hydroxylaldehyde Dimer 
4.11.1 Synthesis of 6-(Benzyloxy)-2'-((S)-1-(((3S,4R,E)-4-hydroxy-7-((4-methoxybenzyl)oxy)-1-phenyl 
hept-1-en-3-yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (16a) and 6-
(benzyloxy)-2'-((S)-1-(((3R,4R,E)-4-hydroxy-7-((4-methoxybenzyl)oxy)-1-phenylhept-1-en-3-
yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (16b) 
To a solution of the above crude Sharpless ADH product 15a in EtOH (0.5 mL) was added 
amine 7 (0.215 g, 0.52 mmol, 1.0 equiv) and -styrenylboronic acid (0.115 g, 0.78 mmol, 1.5 equiv) 
and the mixture was stirred at room temperature for 72 h. The solution was evaporated and the residue 
was dissolved in EtOAc (5 mL) and then washed with sat. aqueous NaHCO3 solution (2 x 5 mL). The 
combined organic layer was dried (MgSO4), filtered and concentrated in vacuo. The crude product 
was purified by column chromatography on silica gel eluting with 1:99 MeOH/CH2Cl2 to afford the 
title compound 16a as a pale yellow oil (0.1437 g, 37%) and 16b as a pale yellow oil (0.134 g, 35%). 
1H NMR analysis revealed the presence of two biphenyl axis rotamers in a 60:40 ratio for both 
products. 16a: Rf = 0.22 (MeOH:CH2Cl2 = 4:96). IR (neat): νmax 3427, 3064, 2935, 2224, 1600, 1512, 
1490, 1179, 1033, 817, 737, 695 cm-1. [𝛼]𝐷
25  + 43 (c 1.2, CHCl3). 1H NMR (500 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 7.52 – 7.44 (m, 1H, H-4), 7.39 (d, J = 2.2 Hz, 
0.6H, H-2), 7.36* (d, J = 2.2 Hz, 0.4H, H-2), 7.32 – 7.11 (m, 10H, ArH), 7.09 – 7.03 (m, 1H, ArH), 
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7.02 (s, 0.6H, H-3′), 7.00* (s, 0.4H, H-3′), 6.93* (d, J = 8.7 Hz, 0.4H, H-5), 6.84 – 6.77 (m, 2.6H, H-5 
and ArH), 6.61 (s, 0.6H, H-6′), 6.55* (s, 0.4H, H-6′), 6.26* (d, J = 16.0 Hz, 0.4H, H-1′′′), 6.03 (d, J = 
16.0 Hz, 0.6H, H-1′′′), 5.93 – 5.81 (m, 1H, H-2′′′), 5.68 – 5.53 (m, 1H, H-3′′), 5.10 – 4.90 (m, 2.6H, 
H-4′′ and PhCH2O (minor) and PhCHAHBO (major)), 4.87 (d, J = 12.4 Hz, 0.4H, PhCHAHBO (major)), 
4.42 – 4.35 (m, 2H, PMPCH2O), 3.91* (s, 1.2H, OCH3), 3.89 (s, 1.8H, OCH3), 3.83* (s, 1.2H, OCH3), 
3.82 (s, 1.8H, OCH3), 3.77* (s, 1.2H, OCH3), 3.75 (s, 1.8H, OCH3), 3.62 (t, J = 6.8 Hz, 0.6H, H-1′′), 
3.55* (dd, J = 8.3, 4.8 Hz, 0.4H, H-1′′), 3.48 – 3.28 (m, 2.4H, H-7′′ and H-4′′′ (minor)), 3.28 – 3.22 
(m, 0.6H, H-4′′′), 3.01* (dd, J = 8.8, 3.0 Hz, 0.4H, H-3′′′), 2.96 (dd, J = 9.4, 3.1 Hz, 0.6H, H-3′′′), 2.45 
– 2.30 (m, 1.6H, H-2′′), 2.30* – 2.20* (m, 0.4H, H-2′′′), 1.77 – 1.56 (m, 1.2H, H-6′′′), 1.51* – 1.42* 
(m, 0.8H, H-6′′′), 1.42* – 1.32* (m, 0.8H, H-5′′′), 1.16 – 1.06 (m, 1.2H, H-5′′′). 13C NMR (125 MHz, 
the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 159.6* (C-6), 159.3 (ArC), 159.19* 
(ArC), 159.16 (C-6), 149.4 (C-4′), 149.2* (C-4′), 147.58* (C-5′), 147.56 (C-5′), 136.8 (ArC), 136.7* 
(ArC), 135.9 (C-2′), 135.9* (C-2), 135.7* (C-2′), 135.5 (C-2), 135.2* (C-3′′), 135.1 (ArC), 135.0 (C-
3′′), 134.3* (ArC), 133.42* (C-4), 133.40 (C-4), 133.0* (C-1′′′), 132.7 (C-1′′′), 132.0* (C-1), 131.5 
(C-1), 130.7* (ArC), 130.6 (ArC), 129.4 (1.2 x ArCH), 129.36* (0.8 x ArCH), 128.73* (0.8 x ArCH), 
128.70 (1.2 x ArCH), 128.66* (0.8 x ArCH), 128.6 (1.2 x ArCH), 128.22* (0.4 x ArCH), 128.16 (0.6 
x ArCH), 128.15* (C-1′), 128.0 (0.6 x ArCH), 127.9 (C-1′), 127.7 (C-2′′′), 127.69* (C-2′′′), 127.3 (0.6 
x ArCH), 126.8* (0.8 x ArCH), 126.6 (1.2 x ArCH), 126.5 (ArCH), 119.0 (C≡N), 118.9* (C≡N), 
117.8 (C-4′′), 117.2* (C-4′′), 113.9 (1.2 x ArCH), 113.8* (0.8 x ArCH), 113.3 (C-5), 112.9* (C-5), 
112.84* (C-6′), 112.80 (C-6′), 109.2* (C-3′), 108.9 (C-3′), 104.3* (C-3), 104.1 (C-3), 72.7 
(PMPCH2O), 72.6* (PMPCH2O), 71.7* (C-4′′′), 71.1 (C-4′′′), 71.1 (C-1′′′), 70.4 (PhCH2O), 70.2 (C-
7′′′), 70.15* (PhCH2O), 63.2* (C-3′′′), 62.0 (C-3′′′), 56.2 (OCH3), 56.1* (OCH3), 56.0* (OCH3), 55.4* 
(OCH3), 55.4 (OCH3 and C-1′′*), 54.9 (C-1′′), 41.3* (C-2′′), 41.2 (C-2′′), 30.6* (C-5′′′), 30.5 (C-5′′′), 
27.2 (C-6′′′), 26.8 (C-6′′′). HRMS (ESI): m/z calcd for C47H51N2O6 [M + H]+: 739.3747; found: 
739.3749. 16b: Rf = 0.31 (MeOH:CH2Cl2 = 4:96). IR (neat): νmax 3409, 2923, 2856, 2225, 1600, 
1512, 1491, 1246, 1178, 1032, 817, 694 cm-1. [𝛼]𝐷
25 - 43 (c 2.4, CHCl3). 1H NMR (500 MHz, the 
asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.54 – 7.44 (m, 1.6H, H-4 and H-2), 
7.40* (s, 0.4H, H-2), 7.35 – 7.00 (m, 13H, ArH and H-3′), 6.94* (d, J = 8.6 Hz, 0.4H, H-5), 6.91 (d, J 
= 8.6 Hz, 0.6H, H-5), 6.79 – 6.76 (m, 2H, ArH), 6.63* (s, 0.4H, H-6′), 6.57 (s, 0.6H, H-6′), 5.88* (d, J 
= 16.0 Hz, 0.4H, H-1′′′), 5.84 (d, J = 16.0 Hz, 0.6H, H-1′′′), 5.67 (dd, J = 16.0, 8.7 Hz, 0.6H, H-2′′′), 
5.64* – 5.55* (m, 0.4H, H-2′′′), 5.55 – 5.45 (m, 1H. , H-3′′), 5.14 – 4.97 (m, 4H, PhCH2O and H-4′′), 
4.37 (s, 1.2H, PMPCH2O), 4.33* (s, 1.8H, PMPCH2O), 3.95 (s, 1.2H, OCH3), 3.93 (s, 1.8H, OCH3), 
3.87 (s, 1.8H, OCH3), 3.80 (s, 1.2H, OCH3), 3.76 (s, 3H, OCH3), 3.63* (dd, J = 9.2, 4.1 Hz, 0.4H, H-
1′′), 3.51 (d, J = 7.4 Hz, 0.8H, H-1′′), 3.43 – 3.20 (m, 2.6H, H-4′′′ and H-7′′′), 3.21* – 3.13* (m, 0.4H, 
H-4′′′), 2.60* (t, J = 8.0 Hz, 0.4H, H-3′′′), 2.51 (t, J = 8.6 Hz, 0.6H, H-3′′′), 2.47 – 2.25 (m, 1.6H, H-
2′′), 2.19* – 2.10* (m, 0.4H, H-2′′), 1.79* – 1.68* (m, 0.4H, H-6′′′), 1.65 – 1.45 (m, 2H, H-6′′′ and H-
5′′′A), 1.42* – 1.33* (m, 0.4H, H-5′′′A), 1.31 – 1.21 (m, 0.6H, H-5′′′B), 1.09* – 1.00* (m, 0.4H, H-
25 
 
5′′′B). 13C NMR (125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 159.8 (C-
6), 159.1 (ArC), 149.4 (C-4′), 149.37* (C-4′), 147.7 (C-5′), 147.4* (C-5′), 136.8* (ArC), 136.4 (ArC), 
135.9 (C-3′′), 135.7* (C-2′), 135.6* (C-3′′), 135.5 (C-2′), 135.2 (C-2), 135.1* (C-2), 134.7 (ArC), 
134.4* (ArC), 133.5 (C-4), 133.3* (C-4), 132.7 (C-1′′′), 132.2 (C-1), 131.6* (C-1′′′), 131.4* (C-1), 
130.7* (ArC), 130.6 (ArC), 129.4 (C-2′′′), 129.3 (1.2 x ArCH), 129.26* (0.8x ArCH), 128.8* (0.8 x 
ArCH), 128.7 (2.4 x ArCH), 128.6* (0.8 x ArCH), 128.57* (C-2′′′), 128.3 (ArCH), 127.8 (C-2), 127.7 
(0.6 x ArCH), 127.7* (0.4 x ArCH), 126.9 (1.2 x ArCH), 126.5* (0.8 x ArCH), 126.4 (1.2 x ArCH), 
126.2* (0.8 x ArCH), 119.0 (C≡N), 118.7* (C-4′′), 118.0 (C-4′′), 113.8 (1.2 x ArCH), 113.77* (0.8 x 
ArCH), 113.0 (C-5), 112.9* (C-5), 112.9 (C-6′), 112.7* (C-6′), 109.5 (C-3′), 109.4* (C-3′), 104.3 (C-
3), 103.9* (C-3), 73.2* (C-4′′′), 73.15 (C-4′′′), 72.5 (PMPCH2O), 72.4* (PMPCH2O), 70.5 (PhCH2O), 
70.2* (PhCH2O), 70.0 (C-7′′′), 69.97* (C-7′′′), 63.3 (C-3′′′), 62.4* (C-3′′′), 56.1 (OCH3), 56.0* 
(OCH3), 55.4 (OCH3), 54.0* (C-1′′), 53.8 (C-1′′), 43.4* (C-2′′), 42.1 (C-2′′), 30.4 (C-5′′′), 30.3* (C-
5′′′), 26.1 (C-6′′′), 26.0* (C-6′′′). HRMS (ESI): m/z calcd for C47H51N2O6 [M + H]+: 739.3747; found: 
739.3741. 
4.12 General Method for Synthesis of Oxazolidinone 
4.12.1 Synthesis of 6-(Benzyloxy)-4',5'-dimethoxy-2'-((S)-1-((4S,5R)-5-(3-((4-
methoxybenzyl)oxy)propyl)-2-oxo-4-((E)-styryl)oxazolidin-3-yl)but-3-en-1-yl)-[1,1'-biphenyl]-3-
carbonitrile (17a) 
To a solution of 16a (29.6 mg, 0.04 mmol, 1.0 equiv) and triethylamine (16.2 mg, 22.3 µL, 
0.16 mmol, 4.0 equiv) in anhydrous CH2Cl2 (0.7 mL) was added triphosgene (5.9 mg, 0.02 mmol, 0.5 
equiv) at 0 °C under a nitrogen atmosphere. After being stirred for 15 min, the reaction mixture was 
allowed to warm to room temperature and stirred for 18 h, and then concentrated in vacuo to give the 
crude product. Purification by column chromatography on silica gel eluting with 30:70 EtOAc/PS 
gave 17a as a light brown solid (33.4 mg, 68%). Rf = 0.34 (EtOAc:hexanes = 40:60). IR (neat): νmax 
3067, 2932, 2223, 1738, 1600, 1512, 1493, 1180, 816, 694 cm-1. [𝛼]𝐷
25 + 71 (c 0.51, CHCl3). 1H NMR 
(500 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.55 (s, 0.63H, H-2), 
7.49* (dd, J = 8.6, 2.1 Hz, 0.37H, H-4), 7.46 (s, 1H, H-3′), 7.41 (dd, J = 8.6, 2.1 Hz, 0.63H , H-4), 
7.38* (s, 0.37H , H-2), 7.36 – 7.04 (m, 11.26H, ArH), 7.01* (d, J = 8.7 Hz, 0.37H, H-5), 6.97* – 
6.92* (m, 0.74H, ArH), 6.86 (d, J = 8.7 Hz, 0.63H , H-5), 6.83 – 6.77 (m, 2H, ArH), 6.67* (s, 0.37H, 
H-6′), 6.56 (s, 0.63H, H-6′), 5.99* (d, J = 15.8 Hz, 0.37H, H-2′′′′′), 5.83 (d, J = 15.8 Hz, 0.63H, H-
2′′′′′), 5.77* – 5.68* (m, 0.37H, H-3′′), 5.68 – 5.52 (m, 1.26H, H-3′′ and H-1′′′′′), 5.41* (dd, J = 15.8, 
8.3 Hz, 0.37H, H-1′′′′′), 5.19 – 4.96 (m, 4H, H-4′′ and PhCH2O), 4.49* – 4.44* (m, 0.37H, H-1′′), 4.37 
(s, 1H, PMPCH2O), 4.34* (s, 1H, PMPCH2O), 4.18 (dd, J = 11.1, 4.5 Hz, 0.63H, H-1′′), 3.98 – 3.92 
(m, 0.63H, H-5′′′), 3.86 (s, 1.89H OCH3), 3.82 (s, 3.78H OCH3), 3.77 (s, 1.11H OCH3), 3.76 (s, 1.11H 
OCH3), 3.72* – 3.64* (m, 0.74H, H-4′′′ and H-5′′′), 3.52 (t, J = 8.2 Hz, 0.63H, H-4′′′), 3.45 – 3.28 (m, 
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2.63H, H-2′′A and H-3′′′′), 3.20* – 3.11* (m, 0.37H, H-2′′A), 2.68* (dt, J = 13.0, 6.0 Hz, 0.37H, H-
2′′B), 2.43 – 2.35 (m, 0.63H, H-2′′B), 1.74 – 1.46 (m, 2.74H, H-2′′′′ and H-1′′′′), 1.33 – 1.31 (m, 1.26H, 
H-1′′′′). 13C NMR (125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 159.6* 
(C-6), 159.4 (C-6), 159.3* (ArC), 159.2 (ArC), 156.8* (C-2′′′), 156.6 (C-2′′′), 149.1 (C-4′), 148.8* (C-
4′), 148.3 (C-5′), 147.9* (C-5′′), 135.8* (ArC), 135.6 (C-3′′′), 135.5 (ArC), 135.4 (C-2), 135.3* (C-2), 
135.26 (ArC), 134.8* (C-3′′′), 134.6 (C-2′′′′′), 133.8* (C-2′′′′′), 133.7* (C-4), 133.6 (C-4), 132.2 (C-
2′), 131.8 (C-1), 131.1* (C-2′), 130.7,* (C-1) 130.5 (ArC), 130.49* (ArC), 129.4 (1.26 x ArCH), 
129.3* (0.74 x ArCH), 128.9* (0.74 x ArCH), 128.8 (1.26 x ArCH), 128.77* (0.74 x ArCH), 128.7 
(2.52x ArCH), 128.67* (0.74 x ArCH), 128.6* (0.37 x ArCH), 128.5 (0.63 x ArCH), 128.3 (ArCH), 
128.0 (C-1′), 127.1* (0.74 x ArCH), 126.9 (1.26 x ArCH), 126.8* (C-1′′′′′), 126.6 (1.26 x ArCH), 
126.5* (0.74 x ArCH), 125.9 (C-1′′′′′), 119.1 (C≡N), 118.9* (C≡N), 118.4* (C-7′′′), 117.6 (C-7′′′), 
113.9 (2 x ArCH), 113.4 (C-5), 113.2* (C-5 and C-6′), 112.9* (C-6′), 111.4 (C-3′), 111.2* (C-3′), 
104.5 (C-3), 104.4* (C-3), 79.0 (C-5′′′), 78.8* (C-5′′′), 72.6 (PMPCH2O), 70.8 (PhCH2O), 70.4* 
(PhCH2O), 69.2* (C-3′′′′), 69.1 (C-3′′′′), 65.1 (C-4′′′), 64.3* (C-4′′′), 56.1 (OCH3), 56.0 (OCH3), 55.4 
(OCH3), 54.5 (C-1′′), 53.8* (C-1′′), 36.3* (C-2′′),  35.5 (C-2′′), 30.6* (C-1′′′′), 29.8 (C-1′′′′), 25.4 (C-
2′′′′). HRMS (ESI): m/z calcd for C48H48N2O7Na [M + Na]+: 787.3359; found: 787.3380. 
4.12.2 6-(Benzyloxy)-4',5'-dimethoxy-2'-((S)-1-((4R,5R)-5-(3-((4-methoxybenzyl)oxy)propyl)-2-oxo-4-
((E)-styryl)oxazolidin-3-yl)but-3-en-1-yl)-[1,1'-biphenyl]-3-carbonitrile (17b) 
Oxazolidinone 17b was prepared from compound 16b (17.9 mg, 0.024 mmol) according to 
the General Method for Synthesis of Oxazolidinone. Purification by column chromatography on silica 
gel eluting with 30:70 EtOAc/hexanes gave the title compound 18 as a pale yellow oil (7.3 mg, 40%). 
1H NMR analysis revealed the presence of two biphenyl axis rotamers in a 53:47 ratio. Rf = 0.34 
(EtOAc:hexanes = 40:60). IR (neat): νmax 2924, 2225, 1740, 1600, 1513, 1491, 1248, 1179, 750, 695 
cm-1. [𝛼]𝐷
25  + 40 (c 0.29, CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal of the minor 
rotamer, CDCl3): δ 7.68* (dd, J = 8.6, 2.2 Hz, 0.47H, H-4), 7.63 (dd, J = 8.6, 2.2 Hz, 0.53H, H-4), 
7.41 – 7.20 (m, 8H, ArH), 7.19 – 7.03 (m, 3H, H-5 and ArH), 6.92* (s, 0.47H, H-3′), 6.90 (s, 0.53H, 
H-3′), 6.81 – 6.75 (m, 2.53H, H-6′ and ArH), 6.69* (s, 0.47H, H-6′), 6.23* (d, J = 15.8 Hz, 0.47H, H-
2′′′′′), 6.14 (d, J = 15.8 Hz, 0.53H, H-2′′′′′), 6.07* (dd, J = 15.8, 9.7 Hz, 0.47H, H-1′′′′′), 6.00 (dd, J = 
15.8, 9.7 Hz, 0.53H, H-1′′′′′), 5.68 – 5.53 (m, 1H, H-3′′), 5.22 (d, J = 12.0 Hz, 0.53H, PhCHAHBO), 
5.12 (d, J = 12.0 Hz, 0.53H, PhCHAHBO), 5.10 – 4.85 (m, 3.94H, H-1′′, H-4′′ and PhCH2O (minor)), 
4.35* (s, 1H, PMPCH2O), 4.30 (s, 1H, PMPCH2O), 4.18* – 4.13* (m, 0.47H, H-5′′′), 3.91 (s, 3H, 
OCH3), 3.85 – 3.78 (m, 0.53H, H-4′′′), 3.77 (s, 4.59H, OCH3), 3.74 (s, 1.41H, OCH3), 3.67* (t, J = 8.9 
Hz, 0.47H, H-4′′′), 3.44 – 3.34 (m, 1.59H, H-3′′′′ and H-5′′′), 3.32* – 3.20* (m, 0.94H, H-3′′′′), 2.83 – 
2.46 (m, 2H, H-2′′), 1.77* – 1.66* (m, 0.47H, H-2′′′′A), 1.61 – 1.45 (m, 2H, H-1′′′′A, H-2′′′′B and H-
2′′′′), 1.45* – 1.35* (m, 0.47H H-1′′′′B), 1.35 – 1.21 (m, 1.06H, H-1′′′′). 13C NMR (125 MHz, the 
asterisk* denotes the signal of the minor rotamer, CDCl3): δ 159.8* (C-6), 159.2* (ArC), 159.15 
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(ArC), 159.0 (C-6), 156.6 (C-2′′′), 156.5* (C-2′′′), 148.3 (C-4′), 148.2 (C-5′), 148.17* (C-4′), 148.1* 
(C-5′), 136.2* (ArC), 135.8 (ArC), 135.5 (ArC), 135.4* (ArC), 135.0* (C-3′′), 134.8* (C-2), 134.7* 
(C-2′′′′′), 134.3 (C-3′′), 134.29 (C-2), 134.2 (C-2′′′′′), 134.15* (C-4), 133.9 (C-4), 131.2 (C-1), 130.9* 
(C-1), 130.7 (C-2′), 130.6 (ArC), 129.9* (C-2′), 129.3 (1.06 x ArCH), 129.2* (0.94 x ArCH), 129.15 
(1.06 x ArCH), 129.1* (0.94 x ArCH), 128.8* (0.47 x ArCH), 128.76 (0.53 x ArCH), 128.7* (0.94 x 
ArCH), 128.66 (1.06 x ArCH), 128.24* (0.47x ArCH), 128.2 (0.53 x ArCH), 128.0 (C-1′), 127.2 
(1.06 x ArCH), 126.7 (1.06 x ArCH), 126.6* (0.94 x ArCH), 126.3* (0.94 x ArCH), 125.8* (C-1′′′′′), 
124.7 (C-1′′′′′), 119.2 (C≡N), 119.0* (C≡N), 118.2* (C-4′′), 117.5 (C-4′′), 113.8 (2 x ArCH), 113.76 
(C-6′), 113.5* (C-5), 113.1 (C-5), 111.1* (C-3′), 111.0 (C-3′), 104.5* (C-3), 104.3 (C-3), 77.5 (C-5′′′), 
77.2* (C-2′′′), 72.4 (PMPCH2O), 70.7 (PhCH2O), 69.8* (PhCH2O), 69.2* (C-3′′′′), 68.8 (C-3′′′′), 
61.3* (C-4′′′), 60.1 (C-4′′′), 56.2* (OCH3), 56.1 (OCH3), 56.0* (OCH3), 55.95 (OCH3), 55.4* (OCH3), 
55.37 (OCH3), 54.1* (C-1′′), 53.8 (C-1′′), 38.3* (C-2′′), 37.3 (C-2′′), 27.9* (C-1′′′′), 27.7 (C-1′′′′), 
26.1* (C-2′′′′), 26.06 (C-2′′′′). HRMS (ESI): m/z calcd for C48H48N2O7Na [M + Na]+: 787.3359; found: 
787.3398. 
4.13 Synthesis of 6-(Benzyloxy)-2'-((S)-1-(((3R,4S,E)-4-hydroxy-7-((4-methoxybenzyl)oxy)-1-
phenylhept-1-en-3-yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (16c) 
Compound 14 (68.0 mg, 0.196 mmol) was treated according to the General Method for 
Sharpless Asymmetric Dihydroxylation (ADH), however AD-mix-α was used instead of AD-mix-β. 
The crude ADH product (15b) was obtained as a brown oil which was used without further 
purification. Alcohol 16c was prepared from the above crude Sharpless ADH product (15b), amine 7 
(31.1 mg, 0.075 mmol, 1.0 equiv) and -styrenylboronic acid (16.7 mg, 0.1125 mmol, 1.5 equiv) 
according to the PBM Reaction with α-Hydroxylaldehyde Dimer. The crude product was purified by 
column chromatography on silica gel eluting with 0.5:99.5 MeOH/CH2Cl2 to afford the title 
compound 16c as a pale yellow oil (37.6 mg, 68%). 1H NMR analysis revealed the presence of two 
biphenyl axis rotamers in a 56:44 ratio. Rf = 0.28 (MeOH:CH2Cl2 = 4:96). IR (neat): νmax 3425, 3065, 
2933, 2223, 1600, 1512, 1246, 1095, 749, 695 cm-1. [𝛼]𝐷
25 - 68 (c 0.06, CHCl3). 1H NMR (500 MHz, 
the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.51 (s, 1H, H-4 and H-2), 7.47* (s, 
0.44H, H-4), 7.45 (s, 0.56H, H-2), 7.39 – 7.09 (m, 13H, ArH and H-3′ ), 6.93 (d, J = 8.7 Hz, 0.56H, 
H-5), 6.88* (d, J = 8.7 Hz, 0.44H, H-5), 6.85 (d, J = 8.6 Hz, 2H, ArH), 6.67* (s, 0.44H, H-6′), 6.61 (s, 
0.56H, H-6′), 6.03 (t, J = 16.0 Hz, 1H, H-1′′′), 5.91 (dd, J = 16.0, 8.3 Hz, 0.56H, H-2′′′), 5.76* (dd, J = 
16.0, 7.5 Hz, 1H, H-2′′′), 5.73 – 5.53 (m, 1H, H-3′′), 5.15* (d, J = 12.4 Hz, 0.88H, H-4′′), 5.12 – 4.98 
(m, 3.12H, H-4′′ and PhCH2O), 4.43 (s, 1.22H, PMPCH2O), 4.40* (s, 0.88H, PMPCH2O), 3.99* (s, 
1.32H, OCH3), 3.98 (s, 1.68H, OCH3), 3.90 (s, 1.68H, OCH3), 3.84* (s, 1.32H, OCH3), 3.81 (s, 3H, 
OCH3), 3.66* (dd, J = 8.9, 4.4 Hz, 0.44H, H-1′′), 3.56 (dd, J = 10.0, 3.0 Hz, 0.56H, H-1′′), 3.52* – 
3.48* (m, 0.44H, H-4′′′), 3.48* – 3.42* (m, 0.88H, H-7′′′), 3.41 – 3.35 (m, 1.68H, H-4′′′ and H-7′′′), 
28 
 
2.92* (dd, J = 7.7, 4.0 Hz, 0.44H, H-3′′′), 2.87 (dd, J = 8.3, 4.0 Hz, 0.56H, H-3′′′), 2.48 – 2.28 (m, 
1.56H, H-2′′), 2.25* – 2.15* (m, 0.44H, H-2′′), 1.83 – 1.47 (m, 2.44H, H-6′′′ and H-5′′′A (minor)), 1.39 
– 1.27 (m, 1.12H, H-5′′′), 1.27 – 1.17 (m, 0.44H H-5′′′B (minor)). 13C NMR (125 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 159.7 (C-6), 159.2* (C-6 and ArC), 159.1* (ArC), 
149.3 (C-4′), 149.2* (C-4′), 147.5 (C-5′), 147.3* (C-5′), 137.0* (ArC), 136.5 (ArC), 136.0 (C-3′′), 
135.8* (C-2′), 135.6 (C-2′), 135.5* (C-3′′), 135.3* (C-2), 135.2 (C-2), 135.0 (ArC), 134.8* (ArC), 
133.4 (C-4), 133.3* (C-4), 132.5 (C-1′′′), 132.1 (C-1), 131.5* (C-1′′′), 131.4* (C-1), 130.5* (ArC), 
129.4 (1.12 x ArCH), 129.3* (0.88 x ArCH), 128.9* (C-2′′′), 128.8* (0.88 x ArCH), 128.7 (1.12 x 
ArCH), 128.66 (1.12 x ArCH), 128.6* (0.88 x ArCH), 128.2 (0.56 x ArCH), 128.15* (0.44x ArCH), 
128.1 (C-2′′′), 127.9 (C-1′), 127.6 (0.56 x ArCH), 127.58* (C-1), 127.5* (0.44 x ArCH), 126.8 (1.12 x 
ArCH), 126.42* (0.88 x ArCH), 126.39 (1.12 x ArCH), 126.2* (0.88 x ArCH), 119.1* (C≡N), 118.9 
(C≡N), 118.4* (C-4′′), 117.8 (C-4′′), 113.83 (1.12 x ArCH), 113.81* (0.88 x ArCH), 113.0 (C-5), 
112.97* (C-5), 112.8 (C-6′), 112.7* (C-6′), 109.6 (C-3′), 109.4* (C-3′), 104.2 (C-3), 103.8* (C-3), 
73.9 (C-4′′′), 72.6 (PMPCH2O), 70.4 (PhCH2O), 70.1* (PhCH2O), 70.0* (C-7′′′), 69.99 (C-7′′′), 62.2 
(C-3′′′), 61.6* (C-3′′′), 56.1 (OCH3), 56.05 (OCH3), 56.0 (OCH3), 55.4 (OCH3), 54.8* (C-1′′), 54.5 (C-
1′′), 43.4* (C-2′′), 42.2 (C-2′′), 30.3 (C-5′′′), 26.6 (C-6′′′). HRMS (ESI): m/z calcd for C47H51N2O6 [M 
+ H]+: 739.3747; found: 739.3777. 
4.14 Synthesis of (R)-N-(2-Bromo-4,5-dimethoxybenzylidene)-2-methylpropane-2-sulfinamide (18) 
To a solution of 4-hydroxy-3-bromobenzonitrile (0.259 g, 1.06 mmol, 1.0 equiv.) in CH2Cl2 
(2 mL) was added potassium hydrogen sulfate (1.45 g, 10.6 mmol, 10.0 equiv.) and (R)-(+)-2-methyl-
2-propanesulfinamide (0.192 g, 1.58 mmol, 1.5 equiv.) and the mixture was stirred at room 
temperature for 24 h. The reaction mixture was filtered through a short pad of celite and concentrated 
in vacuo. Purification by column chromatography on silica gel eluting with 15:85 EtOAc/hexane gave 
the title compound as a white solid (7.3 mg, 40%). Rf = 0.5 (EtOAc:hexane = 50:50). mp: 156-158 °C. 
[𝛼]𝐷
25 - 64.5 (c 0.35, CHCl3). IR (neat): νmax 2958, 2841, 1577, 1507, 1440, 1390, 1255, 1213, 1166, 
1024, 759 cm-1. 1H NMR (500 MHz, CDCl3): δ 8.86 (s, 1H, N=CH), 7.55 (s, 1H, H-6), 7.07 (s, 1H, H-
3), 3.95 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 1.28 (s, 9H, C(CH3)3). 13C NMR (125 MHz, CDCl3): δ 
161.5 (N=CH), 153.0 (C-4), 148.7 (C-5), 125.4 (C-1), 119.0 (C-2), 115.4 (C-3), 110.5 (C-6), 57.8 
(C(CH3)3, 56.4 (OCH3), 56.1 (OCH3), 22.7 (C(CH3)3). HRMS (ESI): m/z calculated for 
C13H18NO3NaSBr [M + Na]+: 370.0088; found: 370.0093. 
4.15 Synthesis of (R)-N-((S)-1-(2-Bromo-4,5-dimethoxyphenyl)but-3-en-1-yl)-2-methylpropane-2-
sulfinamide (19) 
To a solution of N-sulfinyl imine 18 (102 mg, 0.293 mmol) in anhydrous CH2Cl2 (1.5 mL) at -
78 °C was added dropwise allylmagnesium bromide (1.0 M in Et2O, 0.33 mL, 0.323 mmol, 1.1 
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equiv.). After stirring at -78 °C for 4 h, the reaction was quenched at -78 °C with sat. aqueous 
NaHCO3 solution. The aqueous layer was extracted with EtOAc (2 x 5 mL). The combined organic 
layers were dried (MgSO4), filtered and the solvent was concentrated in vacuo. The crude product 
was purified by column chromatography on silica gel eluting with 50:50 EtOAc/hexane to afford the 
title compound as a pale yellow oil (93.2 mg, 82%). Rf = 0.2 (EtOAc:hexane = 50:50). [𝛼]𝐷
25 - 75.7 (c 
0.18, CHCl3). IR (neat): νmax 3224, 2957, 2929, 1603, 1505, 1459, 1384, 1254, 1202, 1158, 1051, 
1026, 925, 869, 795 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.01 (s, 1H, H-3), 6.93 (s, 1H, H-6), 5.87 – 
5.70 (m, 1H, H-3′), 5.25 – 5.16 (m, 2H, H-4′), 4.94 – 4.84 (m, 1H, H-1′), 3.87 (s, 3H, OCH3), 3.84 (s, 
3H, OCH3), 3.69 (s, 1H, NH), 2.70 – 2.58 (m, 1H, H-2′A), 2.44 – 2.34 (m, 1H, H-2′B), 1.23 (s, 9H, 
C(CH3)3). 13C NMR (125 MHz, CDCl3): δ 148.8 (C-4), 148.5 (C-5), 134.1 (C-3′), 132.6 (C-1), 119.5 
(C-4′), 115.5 (C-3), 113.6 (C-2), 111.1 (C-6), 56.2 (OCH3), 56.0 (OCH3), 55.8 (C(CH3)3, 55.5 (C-1′), 
41.9 (C-2′), 22.7 (C(CH3)3). HRMS (ESI): m/z calculated for C16H25NO3SBr [M + H]+: 390.0739; 
found: 390.0737. 
4.16 Synthesis of (S)-1-(2-Bromo-4,5-dimethoxyphenyl)but-3-en-1-amine (20) 
To a solution of sulfinamide 19 (83.3 mg, 0.213 mmol, 1.0 equiv) in MeOH (2 mL) was 
added TMSCl (46.4 mg, 54.2 µL, 0.426 mmol, 2.0 equiv) and the solution was stirred at room 
temperature for 30 min. The solution was then evaporated to dryness in vacuo and the residue was 
washed with Et2O (5 mL) and redissolved in CH2Cl2 (2 mL). The solution was washed with sat. 
aqueous NaHCO3 solution. The organic layer was dried (MgSO4) and concentrated in vacuo to afford 
the title compound as a light brown oil (53.7 mg, 88%) which was used in the next step without 
further purification. The spectroscopic data of this compound matched with those in the literature for 
the racemate.41 Rf = 0.3 (MeOH:CH2Cl2 = 5:95). [𝛼]𝐷
25 - 26.0 (c 0.21, CHCl3). IR (neat): νmax 3363, 
2932, 1602, 1498, 1438, 1380, 1255, 1209, 1152, 1028, 791 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.11 
(s, 1H, H-6), 6.99 (s, 1H, H-3), 5.86 – 5.74 (m, 1H, H-3′), 5.16 (d, J = 17.2 Hz, 1H, H-4′A), 5.12 (d, J 
= 10.2 Hz, 1H, H-4′B), 4.38 (dd, J = 8.6, 4.5 Hz, 1H, H-1′), 3.89 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 
2.54 – 2.47 (m, 1H, H-2′A), 2.28 – 2.19 (m, 1H, H-2′B), 1.77 (s, 2H, NH2). 13C NMR (125 MHz, 
CDCl3): δ 148.7 (C-4), 148.3 (C-5), 136.2 (C-1), 135.2 (C-3′), 118.0 (C-4′), 115.4 (C-3), 112.8 (C-2), 
110.1 (C-6), 56.2 (OCH3), 56.1 (OCH3), 53.3 (C-1′), 42.5 (C-2′). ESIMS m/z 269 (49%) [M(79Br) - 
NH2]+, 271 (51%) [M(81Br) - NH2]+. 
4.17 Synthesis of (3S,4R,E)-3-(((S)-1-(2-Bromo-4,5-dimethoxyphenyl)but-3-en-1-yl)amino)-7-((4-
methoxybenzyl)oxy)-1-phenylhept-1-en-4-ol (21) 
To a solution of the crude Sharpless ADH product 15a in EtOH (0.4 mL) was added amine 20 
(48.7 mg, 0.170 mmol, 1.0 equiv.) and -styrenylboronic acid (37.8 mg, 0.255 mmol, 1.5 equiv.) and 
the solution was stirred at room temperature for 2 d. The reaction mixture was evaporated and 
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dissolved in EtOAc (5 mL) and then washed with sat. aqueous NaHCO3 solution (2 x 5 mL). The 
combined organic layer was dried (MgSO4), filtered and concentrated in vacuo. The crude product 
was purified by column chromatography on silica gel eluting with 2:10:30:58 
MeOH/EtOAc/CH2Cl2/hexane to afford the title compound as a pale yellow oil (45.6 mg, 44%). Rf = 
0.2 (EtOAc:hexane = 50:50). [𝛼]𝐷
25  + 18.0 (c 0.35, CHCl3). IR (neat): νmax 3406, 2932, 1612, 1511, 
1438, 1381, 1247, 1030, 970, 820, 751 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.27 – 7.19 (m, 7H, 
ArH), 6.93 (s, 1H, H-6), 6.90 (s, 1H, H-3), 6.82 (d, J = 8.1 Hz, 2H, ArH), 6.37 (d, J = 16.0 Hz, 1H, H-
1′′), 6.06 (dd, J = 16.0, 8.8 Hz, 1H, H-2′′), 5.82 – 5.73 (m, 1H, H-3′), 5.14 – 5.04 (m, 2H, H-4′), 4.40 
(s, 2H, PMPCH2O), 4.26 (t, J = 6.7 Hz, 1H, H-1′), 3.87 (s, 1H, OH), 3.81 (s, 3H, OCH3), 3.80 – 3.78 
(m, 1H, H-4′′), 3.77 (s, 3H, OCH3), 3.47 – 3.40 (m, 2H, H-7′′), 3.08 (d, J = 8.8 Hz, 1H, H-3′′), 2.48 – 
2.39 (m, 1H, H-2′A), 2.38 – 2.29 (m, 1H, H-2′B), 1.76 (dt, J = 14.0, 6.9 Hz, 1H, H-5′′A), 1.65 (dt, J = 
14.0, 7.1 Hz, 1H, H-5′′B), 1.43 (q, J = 7.1 Hz, 2H, H-6′′). 13C NMR (125 MHz, CDCl3): δ 159.2 
(ArC), 148.7 (C-4), 148.4 (C-5), 136.8 (ArC), 134.9 (C-3′), 134.6 (C-1), 132.8 (C-1′′), 130.5 (ArC), 
129.4 (2 x ArCH), 128.5 (2 x ArCH), 127.6 (ArCH), 127.6 (C-2′′), 126.4 (2 x ArCH), 118.0 (C-4′), 
115.4 (C-3), 113.9 (C-2), 113.8 (2 x ArCH), 110.5 (C-6), 72.6 (PMPCH2O), 71.1 (C-4′′), 70.1 (C-7′′), 
63.2 (C-3′′), 58.0 (C-1′), 56.2 (2 x OCH3), 55.4 (OCH3), 41.5 (C-2′), 30.5 (C-6′′), 26.6 (C-5′′). HRMS 
(ESI): m/z calculated for C33H41NO5Br [M + H]+: 610.2168; found: 610.2192. 
4.18 Synthesis of 6-(Benzyloxy)-4',5'-dimethoxy-2'-((S)-1-((4R,5S)-5-(3-((4-
methoxybenzyl)oxy)propyl)-2-oxo-4-((E)-styryl)oxazolidin-3-yl)but-3-en-1-yl)-[1,1'-biphenyl]-3-
carbonitrile (21) 
Oxazolidinone 21 was prepared from compound 20 (31.4 mg, 0.088 mmol) according to the 
General Method for Synthesis of Oxazolidinone. Purification by column chromatography on silica gel 
eluting with 30:70 EtOAc/hexanes gave the title compound 21 as a pale yellow oil (25.2 mg, 37%). 
1H NMR analysis revealed the presence of two biphenyl axis rotamers in a 67:33 ratio. Rf = 0.24 
(EtOAc:hexanes = 40:60). IR (neat): νmax 2962, 2225, 1737, 1600, 1513, 1492, 1258, 1080, 1012, 793, 
694 cm-1. [𝛼]𝐷
25 - 13 (c 0.21, CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal of the 
minor rotamer, CDCl3): δ 7.52 (d, J = 2.2 Hz, 0.65H, H-2), 7.49 (dd, J = 8.6, 2.2 Hz, 1H, H-4), 7.44 
(s, 0.65H, H-3′), 7.42* (s, 0.35H, H-3′), 7.36* (s, 0.35H, H-2), 7.36 – 7.07 (m, 11.65H, ArH), 7.03* – 
6.98* (m, 0.7H, H-5 and ArH), 6.89 (d, J = 8.6 Hz, 0.65H, H-5), 6.78 (d, J = 8.6 Hz, 2H, ArH), 6.62* 
(s, 0.35H, H-6′), 6.55 (s, 0.65H, H-6′), 5.87* (d, J = 15.9 Hz, 0.35H, H-2′′′′′), 5.76 (d, J = 15.9 Hz, 
0.65H, H-2′′′′′), 5.69 (dd, J = 15.8, 9.2 Hz, 0.65H, H-1′′′′′), 5.65 – 5.51 (m, 1.35H, H-3′′ and H-1′′′′′), 
5.16 – 4.95 (m, 4H, H-4′′ and PhCH2O), 4.38 – 4.31 (m, 2.65H, H-5′′′ and PMPCH2O), 4.22* (dd, J = 
9.6, 6.2 Hz, 0.35H, H-1′′), 4.16 – 4.11 (m, 1H, H-1′′ and H-5′′′), 3.98 – 3.88 (m, 2.05H, H-4′′′ and 
OCH3), 3.85 (s, 1.95H, OCH3), 3.84 (s, 1.95H, OCH3), 3.81* (s, 1.05H, OCH3), 3.78* (s, 1.05H, 
OCH3), 3.76 (s, 1.95H, OCH3), 3.46 – 3.29 (m, 2.65H, H-2′′A and H-3′′′′), 3.26* – 3.18* (m, 0.35H, 
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H-2′′A), 2.71* – 2.61* (m, 0.35H, H-2′′B), 2.41 – 2.34 (m, 0.65H, H-2′′B), 1.81 – 1.37 (m, 4H, H-1′′′′ 
and H-2′′′′). 13C NMR (125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 
159.5 (C-6), 159.3* (ArC), 159.2 (ArC), 157.0* (C-2′′′), 156.7 (C-2′′′), 149.2 (C-4′), 148.3 (C-5′), 
147.9* (C-5′), 135.6* (C-3′′), 135.58 (C-3′′), 135.5* (ArC), 135.48 (ArC), 135.44 (ArC), 135.4 (C-2), 
135.0 (C-2′′′′′), 134.9* (C-2′′′′′), 133.6 (C-4), 132.2 (C-1), 132.17 (C-2′), 131.4* (C-2′), 131.3* (C-1), 
130.6 (ArC), 130.5* (ArC), 129.3 (2 x ArCH), 128.9* (0.7 x ArCH), 128.89 (1.3 x ArCH), 128.8* 
(0.7 x ArCH), 128.7 (1.3 x ArCH), 128.6 (ArCH), 128.3 (ArCH), 127.8 (C-1′), 127.2* (0.7 x ArCH), 
126.8 (1.3 x ArCH), 126.6 (1.3 x ArCH), 126.5* (0.7 x ArCH), 124.1* (C-1′′′′′), 123.6 (C-1′′′′′), 119.1 
(C≡N), 118.8* (C≡N), 118.3* (C-4′′), 117.7 (C-4′′), 113.8 (2 x ArCH), 113.4* (C-5), 113.37 (C-5), 
112.9* (C-6′), 112.8 (C-6′), 111.2 (C-3′), 111.1* (C-3′), 104.4 (C-3), 77.4 (C-5′′′), 72.6* (PMPCH2O), 
72.5 (PMPCH2O), 70.8 (PhCH2O), 70.7* (PhCH2O), 69.2* (C-3′′′), 69.15 (C-3′′′), 62.4 (C-4′′′), 62.1* 
(C-4′′′), 56.1 (OCH3), 56.06 (OCH3), 56.0* (OCH3), 55.98* (OCH3), 55.4 (OCH3), 54.6, (C-1′′) 
54.57* (C-1′′), 37.2* (C-2′′), 35.8 (C-2′′), 28.0 (C-1′′′′), 27.8* (C-1′′′′), 26.2* (C-2′′′′), 26.1 (C-2′′′′). 
HRMS (ESI): m/z calcd for C48H48N2O7Na [M + Na]+: 787.3359; found: 787.3398. 
4.19 Synthesis of 6-(Benzyloxy)-2'-((S)-1-(((3S,4R,E)-4,7-dihydroxy-1-phenylhept-1-en-3-
yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (22) 
To a solution of 1,2-amino alcohol 16a (20.0 mg, 0.027 mmol, 1.0 equiv) in 20:1 
CH2Cl2/water (0.28 mL) was added DDQ (12.3 mg, 0.054 mmol, 2.0 equiv) and the mixture was 
stirred at room temperature for 6 h. The reaction mixture was quenched with sat. aqueous NaHCO3 
solution. The aqueous layer was extracted with DCM (2 x 3 mL). The combined organic layer was 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified 
by column chromatography on silica gel eluting with 2:98 MeOH/CH2Cl2 to afford the title compound 
22 as a light brown oil (7.6 mg, 46%). Rf = 0.22 (MeOH:CH2Cl2 = 5:95). IR (neat): νmax 3333, 2926, 
2224, 1600, 1515, 1120, 733, 695 cm-1. [𝛼]𝐷
25  + 45 (c 0.58, CHCl3). 1H NMR (500 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 7.57 (dd, J = 8.6, 2.2 Hz, 0.51H, H-4), 7.51* (dd, J 
= 8.6, 2.2 Hz, 0.49H, H-4), 7.41 (d, J = 2.2 Hz, 0.51H, H-2), 7.40* (d, J = 2.2 Hz, 0.49H, H-2), 7.34 – 
7.07 (m, 10H, ArH), 7.02* (s, 0.49H, H-3′), 7.00* (d, J = 8.7 Hz, 0.49H, H-5), 6.94 (s, 0.51H, H-3′), 
6.91 (d, J = 8.6 Hz, 0.51H, H-5), 6.63* (s, 0.49H, H-6′), 6.59 (s, 0.51H, H-6′), 6.26 (d, J = 15.9 Hz, 
0.51H, H-1′′′), 6.13* (s, 0.49H, H-1′′′), 5.97* (dd, J = 16.0, 8.7 Hz, 0.49H, H-2′′′), 5.86 (dd, J = 15.9, 
9.2 Hz, 0.51H, H-2′′′), 5.70 – 5.51 (m, 1H, H-3′′), 5.15 – 4.89 (m, 4H, H-4′′ and PhCH2O), 3.90 (s, 
3H, OCH3), 3.86* (s, 1.47H, OCH3), 3.85 (s, 1.53H, OCH3), 3.66 – 3.46 (m, 3H, H-1′′ and H-7′′′), 
3.35* (s, 0.49H, H-4′′′), 3.24 (d, J = 9.2 Hz, 0.51H, H-4′′′), 3.06* (s, 0.49H, H-3′′′), 2.96 (dd, J = 8.7, 
3.0 Hz, 0.51H, H-3′′′), 2.44 – 2.19* (m, 2H, H-2′′), 1.68* – 1.59* (m, 0.98H, H-6′′′), 1.58 – 1.47 (m, 
1.02H, H-6′′′), 1.42 – 1.29 (m, 1.02H, H-5′′′), 1.15 – 0.97* (m, 0.98H, H-5′′′). 13C NMR (125 MHz, 
the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 159.7* (C-6), 159.0 (C-6), 149.33 (C-
4′), 149.3* (C-4′), 147.7* (C-5′), 147.69 (C-5′), 136.4 (ArC), 135.7 (ArC), 135.65 (C-3′′), 135.5 (C-
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2′), 135.4* (C-2), 135.1 (C-2), 134.5* (C-3′′), 133.5 (C-4 and C-1′′′), 133.2* (C-1′′′), 131.8* (C-1), 
131.5 (C-1), 128.7 (2.04 x ArCH), 128.6* (1.96 x ArCH), 128.2 (ArCH), 128.19* (C-1′), 128.1 (C-1′), 
128.0* (0.49 x ArCH), 127.8 (0.51 x ArCH), 126.8* (C-2′′′ and 1.96 x ArCH), 126.5 (2.04 x ArCH), 
126.4 (C-2′′′), 119.1* (C≡N), 118.9 (C≡N), 118.0* (C-4′′), 117.2 (C-4′′), 113.4* (C-5), 113.0 (C-5), 
112.7 (C-6′), 112.6* (C-6′), 108.8* (C-3′), 108.5 (C-3′), 104.4* (C-3), 104.1 (C-3), 70.9* (C-4′′′), 70.8 
(C-4′′′), 70.4 (PhCH2O), 70.3 (PhCH2O), 62.9 (C-7′′′), 62.8* (C-7′′′ and C-3′′′), 62.3 (C-3′′′), 56.1* 
(OCH3), 56.0 (OCH3), 55.1* (C-1′′), 55.0 (C-1′′), 41.0 (C-2′′), 30.7* (C-5′′′), 30.6 (C-5′′′), 30.3* (C-
6′′′), 30.2 (C-6′′′). HRMS (ESI): m/z calcd for C39H43N2O5 [M + H]+: 619.3172; found: 619.3174. 
4.16 General Method for Mesylation-Cyclization 
4.16.1 Synthesis of 6-(Benzyloxy)-2'-((S)-1-((2S,3R)-3-hydroxy-2-((E)-styryl)piperidin-1-yl)but-3-en-
1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (23) 
To a solution of diol 22 (45.3 mg, 0.073 mmol, 1.0 equiv) in anhydrous CH2Cl2 (0.73 mL) at 
0 °C was added triethylamine (7.4 mg, 10.2 µL, 0.073 mmol, 1.0 equiv) and then dropwise 
methanesulfonyl chloride (7.4 mg, 10.2 µL, 0.073 mmol, 1.0 equiv). The reaction mixture was stirred 
for 5 min then warmed up to 45 °C and stirred for 18 h. After the reaction had completed, the mixture 
was concentrated in vacuo. The crude product was purified by column chromatography on silica gel 
eluting with 2:98 MeOH/CH2Cl2 to afford the title compound 23 as a light green oil (23.8 mg, 54%) 
and recovered diol 22 as a pale yellow oil (13.8 mg, 31%). 1H NMR analysis revealed the presence of 
two biphenyl axis rotamers in a 67:33 ratio. Rf = 0.27 (MeOH:CH2Cl2 = 3:97). IR (neat): νmax 3351, 
2930, 2224, 1600, 1514, 1258, 1122, 1024, 746, 695 cm-1. [𝛼]𝐷
25  + 18 (c 0.14, CHCl3). 1H NMR (500 
MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.65 (dd, J = 8.6, 2.2 Hz, 1H, 
H-4), 7.54 (d, J = 2.2 Hz, 1H, H-2), 7.45 – 7.10 (m, 8H, ArH), 7.04* (d, J = 8.5 Hz, 0.33H, H-5), 
6.96* (s, 0.33H, H-3′′), 6.91 – 6.88 (m, 2H, ArH), 6.87 (s, 0.67H, H-3′′), 6.81 (d, J = 8.6 Hz, 0.67H, 
H-5), 6.65* (s, 0.33H, H-6′), 6.61 (s, 0.67H, H-6′), 6.58 (d, J = 15.8 Hz, 1H, H-2′′′′), 5.65* – 5.50* 
(m, 0.33H, H-3′′), 5.30 (ddt, J = 16.9, 10.0, 6.8 Hz, 0.67H, H-3′′), 5.13* (d, J = 12.4 Hz, 0.33H, 
PhCHAHBO (minor)), 5.07* (d, J = 12.4 Hz, 0.33H, PhCHAHBO (minor)), 5.00* – 4.92* (m, 0.33H, 
H-4′′A), 4.85 (dd, J = 17.1, 2.0 Hz, 1H, H-4′′B (minor) and H-4′′A), 4.75 (dd, J = 15.8, 9.3 Hz, 1H, H-
1′′′′), 4.69 (d, J = 12.5 Hz, 0.67H, PhCHAHBO), 4.59 (d, J = 11.6 Hz, 1.34H, H-4′′B and PhCHAHBO), 
3.93* (s, 0.99H, OCH3), 3.93 (s, 2.01H, OCH3), 3.89 – 3.85* (m, 0.33H, H-1′′), 3.84 (s, 2.01H, 
OCH3), 3.82* (s, 0.99H, OCH3), 3.75 (dd, J = 11.0, 3.9 Hz, 0.67H, H-1′′), 3.17 – 3.10 (m, 1H, H-3′′′), 
3.08* – 2.98* (m, 0.33H, H-2′′′), 2.84 (t, J = 8.4 Hz, 0.67H, H-2′′′), 2.64 (d, J = 11.3 Hz, 0.67H, H-
6′′′A), 2.58* – 2.49* (m, 0.66H, H-2′′), 2.48 – 2.40 (m, 1.34H, H-2′′), 2.40* – 2.33* (m, 0.33H, H-
6′′′A), 2.13 (t, J = 9.6 Hz, 0.67H, H-6′′′B), 2.08* – 1.96* (m, 0.99H, H-4′′′ and H-6′′′B), 1.63* – 1.53* 
(m, 0.66H, H-5′′′), 1.32 – 1.16 (m, 2.68H, H-4′′′ and H-5′′′). 13C NMR (125 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 160.2* (C-6), 159.1 (C-6), 147.9* (C-4′), 147.6 (C-
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4′), 147.4 (C-5′), 147.2* (C-5′), 137.3 (C-2), 136.5 (ArC), 136.1* (ArC), 136.0 (C-3′′), 135.8 (ArC), 
135.6* (C-3′′), 135.0* (C-2′′′′), 134.8 (C-2′′′′), 133.2* (C-4), 132.8 (C-4), 132.7* (C-1), 132.4 (C-1), 
131.5* (C-2′), 131.2 (C-2′), 130.9 (C-1′), 130.1* (C-1′), 129.0* (0.66 x ArCH), 128.7* (0.66 x ArCH), 
128.6 (1.34 x ArCH), 128.5 (1.34 x ArCH), 128.2* (0.33 x ArCH), 128.1* (0.33 x ArCH), 128.07 
(0.67 x ArCH), 127.9 (0.67 x ArCH), 126.8 (1.34 x ArCH), 126.6* (0.66 x ArCH), 126.5* (0.66 x 
ArCH), 126.47 (1.34 x ArCH), 119.3 (C≡N), 119.1* (C≡N), 117.3* (C-4′′), 116.3 (C-4′′), 113.9* (C-
6′), 113.8 (C-6′), 113.0 (C-5), 112.8* (C-5), 111.9 (C-3′), 111.8* (C-3′), 103.8* (C-3), 103.5 (C-3), 
70.9 (C-3′′′), 70.5* (C-2′′′), 70.4 (C-2′′′), 70.1* (PhCH2O), 70.0 (PhCH2O), 60.2* (C-1′′), 60.1 (C-1′′), 
56.2 (OCH3), 56.0* (OCH3), 44.5* (C-6′′′), 44.1 (C-6′′′), 31.6 (C-4′′′), 30.4* (C-4′′′), 27.5 (C-2′′), 23.4 
(C-5′′′), 22.3* (C-5′′′). HRMS (ESI): m/z calcd for C39H41N2O4 [M + H]+: 601.3066; found: 601.3086. 
4.17 General Method for Ring-Closing Metathesis 
4.17.1 Synthesis of 6-(Benzyloxy)-2'-((1R,6S,9aS)-1-hydroxy-1,3,4,6,7,9a-hexahydro-2H-quinolizin-6-
yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (24)  
To a solution of carbonitrile 23 (15.8 mg, 0.026 mmol, 1.0 equiv) in N2 purged anhydrous 
CH2Cl2 (0.26 mL) was added Ti(OiPr)4 (7.5 mg, 0.026 mmol, 1.0 equiv) and Grubbs’ II ruthenium 
catalyst (4.1 mg, 0.0053 mmol, 0.18 equiv) and the mixture was stirred and heated at 50 °C for 8 h. 
The reaction mixture was then cooled to room temperature and the solvent was evaporated. The crude 
product was purified by column chromatography on silica gel eluting with 3:97 MeOH/CH2Cl2 to 
afford the title compound 24 as a light brown oil (5.2 mg, 40%). 1H NMR analysis revealed the 
presence of two biphenyl axis rotamers in a 75:25 ratio. Rf = 0.22 (MeOH:CH2Cl2 = 5:95). IR (neat): 
νmax 3351, 2928, 2224, 1600, 1514, 1490, 1253, 1035, 731, 696 cm-1. [𝛼]𝐷
25  - 71 (c 0.27, CHCl3). 1H 
NMR (500 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.59 (d, J = 9.0 Hz, 
1H, H-4), 7.54 (d, J = 2.2 Hz, 1H, H-2), 7.35 – 7.13 (m, 5H, ArH), 7.13 – 7.07 (m, 1.25H, H-5 and H-
3′), 6.98 (d, J = 8.6 Hz, 0.75H, H-5), 6.69* (s, 0.25H, H-6′), 6.58 (s, 0.75H, H-6′), 6.20 – 6.11 (m, 1H, 
H-9′′), 6.02* (d, J = 9.1 Hz, 0.25H, H-8′′), 5.92 (d, J = 10.1 Hz, 0.75H, H-8′′), 5.18* (d, J = 12.4 Hz, 
0.25H, PhCHAHBO (minor)), 5.13 – 5.01 (m, 1.75H PhCHAHBO (minor) and PhCH2O), 4.02* (d, J = 
6.1 Hz, 0.25H, H-6′′), 3.88 (s, 2.25H, OCH3), 3.86* (s, 0.75H, OCH3), 3.84 (s, 2.25H, OCH3), 3.82 – 
3.79 (m, 0.75H, H-6′′), 3.79* (s, 0.75H, OCH3), 3.29 (br s, 1H, H-1′′), 2.76 – 2.58 (m, 2H, H-7′′A 
(minor), H-7′′A and H-9a′′), 2.32* – 2.25* (m, 0.25H, H-7′′B (minor),), 2.22 – 1.77 (m, 4.75H, H-2′′, 
H-3′′A, H-2′′ and H-7′′B), 1.53 – 1.09 (m, 2H, H-3′′B, H-2′′ (minor)).13C NMR (125 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 159.6* (C-6), 159.4 (C-6), 149.0 (C-4′), 147.6 (C-
5′), 135.8 (ArC), 135.7 (C-2), 133.3 (C-4), 133.1 (C-1), 132.54* (C-1), 132.5 (C-1′), 131.9* (C-1′), 
128.8 (2 x ArCH), 128.6 (C-2′), 128.3 (ArCH), 127.0 (2 x ArCH), 126.4 (C-9′′), 126.2* (C-8′′), 125.8 
(C-8′′), 119.3 (C≡N), 113.2* (C-5 and C-6), 112.9 (C-5), 112.8 (C-6), 110.4* (C-3′), 110.2 (C-3′), 
104.5 (C-3), 71.7 (C-1′′), 71.2* (C-1′′), 70.8 (PhCH2O), 70.3* (PhCH2O), 61.2 (C-9a′′), 56.1 (C-6′′), 
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56.0 (2 x OCH3), 54.6* (C-6′′), 51.1 (C-4′′), 50.3* (C-4′′), 34.5 (C-2′′), 31.9 (C-7′′), 23.6 (C-3′′), 22.8 
(C-3′′). HRMS (ESI): m/z calcd for C31H33N2O4 [M + H]+: 497.2440; found: 497.2454. 
tert-Butyldimethyl(pent-4-en-1-yloxy)silane (25).34 To a solution of 4-penten-1-ol (2.15 g, 25.0 mmol, 
1.0 equiv) in CH2Cl2 (25 mL) was added imidazole (2.04 g, 30.0 mmol, 1.2 equiv) followed by 
TBSCl (4.52 g, 30.0 mmol, 1.2 equiv) and the reaction mixture was stirred at room temperature for 3 
h. After the reaction had completed, water (30 mL) was added and the mixture was extracted with 
EtOAc (2 x 30 mL). The organic layer was dried (MgSO4) and concentrated in vacuo. The crude 
product was purified by column chromatography on silica gel eluting with 1:99 Et2O/hexanes to 
afford the title compound 25 as a colorless oil (4.91 g, 98%). The spectroscopic data of this compound 
matched with those in the literature.34 1H NMR (500 MHz, CDCl3): δ 5.82 (ddt, J = 17.0, 10.2, 6.7 Hz, 
1H, H-4), 5.02 (d, J = 17.0 Hz, 1H, H-5A), 4.95 (d, J = 10.2 Hz, 1H, H-5B), 3.62 (t, J = 6.5 Hz, 2H, H-
1), 2.10 (q, J = 7.3 Hz, 2H, H-3), 1.61 (p, J = 6.9 Hz, 2H, H-2), 0.90 (s, 9H, (CH3)3CSi), 0.05 (s, 6H, 2 
x CH3Si). 
4.18 Synthesis of (E)-tert-Butyldimethyl((5-(phenylsulfonyl)pent-4-en-1-yl)oxy)silane (26) 
Sulfone 26 was prepared from compound 25 (0.401 g, 2.0 mmol) according to the General 
Method for Olefin Cross Metathesis. Purification by column chromatography on silica gel eluting 
with 10:10:80 Et2O/CH2Cl2/hexanes gave the title compound 26 as a colorless oil (0.432 g, 63%). Rf = 
0.16 (Et2O:CH2Cl2:hexanes = 10:10:80). IR (neat): νmax 2929, 2858, 1643, 1473, 1256, 1099, 911 833, 
774 cm-1. 1H NMR (500 MHz, CDCl3): δ δ 7.88 (d, J = 7.1 Hz, 2H, ArH), 7.61 (t, J = 7.6 Hz, 1H, 
ArH), 7.53 (t, J = 7.8 Hz, 2H, ArH), 7.01 (dt, J = 15.0, 6.9 Hz, 1H, H-4), 6.33 (d, J = 15.0 Hz, 1H, H-
5), 3.60 (t, J = 6.0 Hz, 2H, H-1), 2.33 (q, J = 8.3, 7.7 Hz, 2H, H-3), 1.71 – 1.62 (m, 2H, H-2), 0.87 (s, 
9H, (CH3)3CSi), 0.01 (s, 6H, 2 x CH3Si). 13C NMR (125 MHz, CDCl3): δ 147.0 (C-4), 140.9 (ArC), 
133.3 (ArCH), 130.8 (C-5), 129.4 (2 x ArCH), 127.7 (2 x ArCH), 61.9 (C-1), 30.8 (C-2), 28.2 (C-3), 
26.0 ((CH3)3CSi), 18.4 ((CH3)3CSi), -5.2 (2 x CH3Si). HRMS (ESI): m/z calcd for C17H29O3SSi [M + 
H]+: 341.1607; found: 341.1622. 
4.19 Synthesis of 6-(Benzyloxy)-2'-((S)-1-(((3S,4R,E)-7-((tert-butyldimethyl silyl)oxy)-4-hydroxy-1-
phenylhept-1-en-3-yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (28a) and 
6-(benzyloxy)-2'-((S)-1-(((3R,4R,E)-7-((tert-butyldimethylsilyl)oxy)-4-hydroxy-1-phenylhept-1-en-3-
yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (28b) 
Aldehyde 27 was prepared from compound 26 (68.0 mg, 0.196 mmol) according to the 
General Method for Sharpless Asymmetric Dihydroxylation (ADH). The crude ADH product was 
used without further purification. Alcohol 28a and 28b were prepared from the above crude Sharpless 
ADH product 27, amine 7 (1.0350 g, 2.5 mmol, 1.0 equiv) and (E)-2-phenylvinylboronic acid (0.7400 
g, 5.0 mmol, 2.0 equiv) according to the PBM Reaction with α-Hydroxylaldehyde Dimer. The crude 
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product was purified by column chromatography on silica gel eluting with 0:100 to 2:98 
MeOH/CH2Cl2 to afford the title compound 28a (0.7813 g, 43%), as a pale yellow oil and compound 
28b (0.6328 g, 35%), as a pale yellow oil. 1H NMR analysis revealed the presence of two biphenyl 
axis rotamers in a 57:43 ratio for compound 28a and in a 59:41 ratio for compound 28b. 28a: Rf = 
0.20 (EtOAc:hexanes = 30:70). IR (neat): νmax 3491, 3023, 2926, 22 26, 1600, 1515, 1248, 1034, 967, 
834, 749, 693 cm-1. [𝛼]𝐷
25  - 74 (c 2.3, CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal of 
the minor rotamer, CDCl3): δ 7.50* (d, J = 8.7 Hz, 0.43H, H-4), 7.44 (d, J = 8.7 Hz, 0.57H, H-4), 7.40 
(s, 0.57H, H-2), 7.37* (s, 0.43H, H-2), 7.34 – 7.03 (m, 11H, H-3′ and ArH), 6.94 (d, J = 8.7 Hz, 
0.57H, H-5), 6.83* (d, J = 8.7 Hz, 0.43H, H-5), 6.61 (s, 0.57H, H-6′), 6.56* (s, 0.43H, H-6′), 6.28* (d, 
J = 16.0 Hz, 0.43H, H-1′′′), 6.12 (d, J = 15.9 Hz, 0.57H, H-1′′′), 5.93 – 5.81 (m, 1H, H-2′′′), 5.70 – 
5.48 (m, 1H, H-3′′), 5.12 – 4.89 (m, 4H, H-4′′ and PhCH2O), 3.92* (s, 1.29H, OCH3), 3.90* (s, 1.29H, 
OCH3), 3.84 (s, 3.42H, OCH3), 3.65* (t, J = 5.8 Hz, 0.86H, H-7′′′), 3.62 – 3.56 (m, 1H, H-1′′), 3.53 (t, 
J = 6.3 Hz, 1.14H, H-7′′′), 3.45 – 3.37 (m, 1H, H-4′′′), 3.08 – 3.00 (m, 1H, H-3′′′), 2.42 – 2.33 (m, 
1.57H, H-2′′ and H-2′′A (minor)), 2.32* – 2.23* (m, 0.43H, H-2′′B (minor)), 1.67 – 1.51 (m, 1.14H, H-
6′′′), 1.50 – 1.35 (m, 2H, H-5′′′ and H-6′′′), 1.23* – 1.10* (m, 0.86H, H-5′′′), 0.85 (s, 9H, (CH3)3CSi), 
0.02* (s, 2.58H, CH3Si), 0.02 (s, 3.42H, CH3Si).13C NMR (125 MHz, the asterisk* denotes the signal 
of the minor rotamer, CDCl3): δ 159.6 (C-6), 159.0* (C-6), 149.3* (C-4′), 149.2 (C-4′), 147.6* (C-5′), 
147.5 (C-5′), 136.8* (ArC), 136.7 (ArC), 135.8 (C-3′′ and ArC), 135.7* (ArC), 135.5* (C-2), 135.2 
(C-2), 134.9* (C-3′′), 134.2 (C-2′), 133.4* (C-4), 133.3 (C-4), 133.0* (C-1′′′), 132.5 (C-1′′′), 131.9* 
(C-1), 131.7 (C-1), 128.7 (1.14 x ArCH), 128.7* (0.86 x ArCH), 128.6 (1.14 x ArCH), 128.6* (0.86 x 
ArCH), 128.2 (1.14 x ArCH), 128.2* (0.86 x ArCH), 128.0* (C-1′), 127.9 (C-1′), 127.7* (C-2′′′), 
127.6 (C-2′′′), 126.8* (0.86 x ArCH), 126.5* (0.86 x ArCH), 126.5 (2.28 x ArCH), 118.9* (C≡N), 
118.9 (C≡N), 117.8* (C-4′′), 117.2 (C-4′′), 113.3 (C-5), 112.9 (C-5), 112.8 (C-6′), 112.7* (C-6′), 
109.3* (C-3′), 109.2 (C-3′), 104.2 (C-3), 71.8 (C-4′′′), 71.4* (C-4′′′), 70.4 (PhCH2O), 70.3* 
(PhCH2O), 63.5* (C-7′′′), 63.4 (C-7′′′), 63.3 (C-3′′′), 62.2* (C-3′′′), 56.1 (OCH3), 56.1* (OCH3), 56.0* 
(OCH3), 55.4 (C-1′′), 55.1* (C-1′′), 41.2* (C-2′′), 41.0 (C-2′′), 30.6 (C-5′′′), 30.5* (C-5′′′), 29.9 (C-
6′′′), 29.7* (C-6′′′), 26.0 ((CH3)3CSi), 18.4 ((CH3)3CSi), 18.4* ((CH3)3CSi), -5.2 (CH3Si), -5.2* 
(CH3Si). HRMS (ESI): m/z calcd for C45H57N2O5Si [M + H]+: 733.4037; found: 733.4058. 
28b: Rf = 0.39 (MeOH:CH2Cl2 = 5:95). IR (neat): νmax 3510, 2930, 2225, 1600, 1510, 1251, 
1095, 695 cm-1. [𝛼]𝐷
25  + 20 (c 0.18, CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal of 
the minor rotamer, CDCl3): δ 7.50 (d, J = 2.0 Hz, 0.59H, H-2), 7.49* (dd, J = 8.6, 1.9 Hz, 0.41H, H-
4), 7.46 (dd, J = 8.6, 2.1 Hz, 0.59H, H-4), 7.40* (d, J = 2.1 Hz, 0.41H, H-2), 7.34 – 7.19 (m, 8.36H, 
ArH), 7.17* (d, J = 7.4 Hz, 0.82H, ArH), 7.13 – 7.09 (m, 1.82H, H-3′ and ArH), 7.04* (d, J = 7.5 Hz, 
0.82H, ArH), 6.92 (t, J = 8.6 Hz, 1H, H-5), 6.63* (s, 0.41H, H-6′), 6.57 (s, 0.59H, H-6′), 5.91* (d, J = 
16.0 Hz, 0.41H, H-1′′′), 5.86 (d, J = 15.9 Hz, 0.59H, H-1′′′), 5.67 (dd, J = 15.9, 8.6 Hz, 059H, H-2′′′), 
5.59* (dd, J = 16.0, 7.7 Hz, 0.41H, H-2′′′), 5.63 – 5.45 (m, 1H, H-3′′), 5.16* – 5.08* (m, 0.41H, H-
36 
 
4′′), 5.08 – 4.96 (m, 2.59H, H-4′′ and PhCH2O), 3.96* (s, 1.23H, OCH3), 3.94 (s, 1.77H, OCH3), 3.87 
(s, 1.77H, OCH3), 3.80* (s, 1.23H, OCH3), 3.63* (dd, J = 9.3, 4.3 Hz, 0.41H, H-1′′), 3.60 – 3.39 (m, 
2.59H, H-1′′ and H-7′′′), 3.24 (td, J = 8.5, 2.4 Hz, 0.59H, H-4′′′), 3.17* (td, J = 8.0, 2.5 Hz, 0.41H, H-
4′′′), 2.61* (t, J = 8.0 Hz, 0.41H, H-3′′′), 2.53 (t, J = 8.5 Hz, 0.59H, H-3′′′), 2.46 – 2.23 (m, 1.41H, H-
2′′ (minor) and H-2′′A), 2.14 (dt, J = 14.5, 9.6 Hz, 0.59H, H-2′′B), 1.71 – 1.33 (m, 2H, H-6′′′), 1.24 – 
0.98 (m, 2H, H-5′′′), 0.81 (s, 9H, (CH3)3CSi), -0.02* (s, 1.23H, CH3Si), -0.02 (s, 1.77H, CH3Si), -0.03 
(s, 1.77H, CH3Si), -0.03* (s, 1.23H, CH3Si).13C NMR (125 MHz, the asterisk* denotes the signal of 
the minor rotamer, CDCl3): δ 159.8 (C-6), 159.2* (C-6), 149.5 (C-4′), 149.4* (C-4′), 147.7 (C-5′), 
147.4* (C-5′), 136.9 (ArC), 136.4 (ArC), 136.0* (C-3′′), 135.7* (C-2′), 135.6* (C-2), 135.6 (C-2′), 
135.3 (C-3′′), 135.2 (C-2), 134.8 (ArC), 134.5* (ArC), 133.4 (C-4), 133.3* (C-4), 132.7 (C-1′′′), 132.3 
(C-1), 131.6* (C-1′′′), 131.5 (C-1), 129.6* (C-2′′′), 128.8* (0.82 x ArCH), 128.76 (C-2′′′), 128.7 (1.18 
x ArCH), 128.68 (1.18 x ArCH), 128.6* (0.82 x ArCH), 128.3 (ArCH), 127.9 (C-2), 127.7 (0.59 x 
ArCH), 127.68* (C-2), 127.6* (0.41 x ArCH), 126.9 (1.18 x ArCH), 126.5* (0.82 x ArCH), 126.4 
(1.18 x ArCH), 126.2* (0.82 x ArCH), 119.0* (C≡N), 118.9 (C≡N), 118.6* (C-4′′), 117.9 (C-4′′), 
113.1 (C-5), 113.0* (C-5), 112.9 (C-6′), 112.7* (C-6′), 109.6 (C-3′), 109.5* (C-3′), 104.4 (C-3), 103.9 
(C-3), 73.5* (C-4′′′), 73.4 (C-4′′′), 70.5 (PhCH2O), 70.2 (PhCH2O), 63.4 (C-3′′′), 63.3 (C-7′′′), 63.2* 
(C-7′′′), 62.5* (C-3′′′), 56.1 (OCH3), 56.08 (OCH3), 54.1* (C-1′′), 53.9 (C-1′′), 43.5* (C-2′′), 42.2 (C-
2′′), 30.2 (C-5′′′), 30.1* (C-5′′′), 29.2 (C-6′′′), 29.1* (C-6′′′), 26.0 ((CH3)3CSi), 18.4 ((CH3)3CSi), -5.2 
(2 x CH3Si). HRMS (ESI): m/z calcd for C45H57N2O5Si [M + H]+: 733.4037; found: 733.4042. 
4.20 General Method for the Silylation of a Secondary Alcohol 
4.20.1 Synthesis of 6-(Benzyloxy)-2'-((S)-1-(((3S,4R,E)-4,7-bis((tert-butyldimethylsilyl)oxy)-1-
phenylhept-1-en-3-yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (29a) 
To a solution of 1,2-amino alcohol 28a (0.446 g, 0.608 mmol, 1.0 equiv) in anhydrous 
CH2Cl2 (1.5 mL) was added imidazole (0.331 g, 4.866 mmol, 8.0 equiv) followed by TBSCl (0.550 g, 
3.649 mmol, 6.0 equiv) and the reaction mixture was stirred at 50 °C for 20 h. The reaction was 
quenched with sat. aqueous NH4Cl solution and extracted with CH2Cl2 (2 x 2 mL). The organic layer 
was washed with water, brine, dried (MgSO4), and concentrated in vacuo. The crude product was 
purified by column chromatography on silica gel eluting with 15:85 EtOAc/hexanes to afford the title 
compound 29a as a pale yellow oil (0.453 g, 88%). 1H NMR analysis revealed the presence of two 
biphenyl axis rotamers in a 58:42 ratio. Rf = 0.28 (EtOAc:hexanes = 20:80). IR (neat): νmax 2928, 
2225, 1600, 1514, 1037, 834, 693 cm-1. [𝛼]𝐷
25  + 11 (c 1.7, CHCl3). 1H NMR (500 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 7.38* (dd, J = 8.7, 2.1 Hz, 0.42H, H-4), 7.36* (d, J 
= 2.1 Hz, 0.42H, H-2), 7.34 – 7.00 (m, 12.16H, H-2, H-4, H-3′ and ArH), 6.84 (d, J = 8.6 Hz, 0.58H, 
H-5), 6.53* (s, 0.42H, H-6′), 6.45 (s, 0.58H, H-6′), 6.43* (d, J = 8.7 Hz, 0.42H, H-5), 6.18 (d, J = 16.0 
Hz, 0.58H, H-1′′′), 6.06* (d, J = 16.0 Hz, 0.42H, H-1′′′), 5.76* (dd, J = 16.0, 9.1 Hz, 0.42H, H-2′′′), 
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5.62 (dd, J = 16.0, 8.7 Hz, 0.58H, H-2′′′), 5.60 – 5.50 (m, 1H, H-3′′), 5.08 – 4.90 (m, 2.32H, H-4′′ and 
PhCH2O), 4.89* – 4.76* (m, 1.68H, H-4′′ and PhCH2O), 3.95 (s, 1.74H, OCH3), 3.91* (s, 1.26H, 
OCH3), 3.79* (s, 1.26H, OCH3), 3.75 (s, 1.74H, OCH3), 3.70* – 3.66* (m, 0.42H, H-4′′′), 3.66 – 3.61 
(m, 0.58H, H-4′′′), 3.59 – 3.47 (m, 2.58H, H-1′′ and H-7′′′), 3.43* (dd, J = 7.7, 5.2 Hz, 0.42H, H-1′′), 
3.18 (dd, J = 8.7, 3.3 Hz, 0.58H, H-3′′′), 3.07* (dd, J = 9.2, 3.4 Hz, 0.42H, H-3′′′), 2.42 – 2.23 (m, 2H, 
H-2′′), 1.77 (br s, 1H, NH), 1.68 – 1.32 (m, 4H, H-5′′′ and H-6′′′), 0.87 (s, 5.22H, (CH3)3CSi), 0.85* 
(s, 3.78H, (CH3)3CSi), 0.85 (s, 5.22H, (CH3)3CSi), 0.79* (s, 3.78H, (CH3)3CSi), 0.05* (s, 2.52H, 
CH3Si), 0.04 (s, 3.48H, CH3Si), 0.00* (s, 3.48H, CH3Si), -0.01* (s, 2.52H, CH3Si). 13C NMR (125 
MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 159.6 (C-6), 159.0* (C-6), 
148.9* (C-4′), 148.8 (C-4′), 147.3 (C-5′), 147.2* (C-5′), 137.5* (ArC), 137.0 (ArC), 136.2 (ArC), 
136.1* (ArC), 136.1 (C-3′′), 135.9 (C-2′), 135.7* (C-2), 135.4* (C-3′′), 135.37* (C-2′), 135.2 (C-2), 
133.1 (C-4), 132.9* (C-4), 132.0 (C-1), 131.9* (C-1′′′), 131.1 (C-1′′′), 130.6 (C-2′′′), 129.0* (C-2′′′), 
128.7 (1.16 x ArCH), 128.66 (1.16 x ArCH), 128.5 * (0.84 x ArCH), 128.45 * (0.84 x ArCH), 128.1 
(0.58 x ArCH), 128.0 * (0.42 x ArCH), 127.4 (C-1), 127.3 (ArCH), 126.7 (1.16 x ArCH), 126.5* 
(0.84 x ArCH), 126.45 (1.16 x ArCH), 126.4* (0.84x ArCH), 119.2* (C≡N), 119.0 (C≡N), 117.3* (C-
4′′), 117.2 (C-4′′), 113.2* (C-5), 112.8 (C-5), 112.7 (C-6′), 112.4* (C-64′), 110.5 (C-3′), 110.2* (C-3′), 
104.0 (C-3), 103.6* (C-3), 76.2 (C-4′′′), 75.8* (C-4′′′), 70.3 (PhCH2O), 70.0* (PhCH2O), 65.0 (C-3′′), 
63.3 (C-7′′′), 63.28* (C-7′′′), 61.6* (C-3′′), 56.7 (C-1′′), 56.1 (OCH3), 56.0 (OCH3), 55.97* (OCH3), 
55.9* (OCH3), 55.2* (C-1′′), 41.4 (C-2′′), 41.2* (C-2′′), 31.1* (C-6′′′), 29.5 (C-6′′′), 29.3 (C-5′′′), 
28.8* (C-5′′′), 26.1 ((CH3)3CSi), 26.0 ((CH3)3CSi), 18.4 ((CH3)3CSi), 18.2 ((CH3)3CSi), -3.9* 
(CH3Si), -4.08 (CH3Si), -4.1 (CH3Si), -4.3* (CH3Si), -5.16 (CH3Si), -5.2* (CH3Si). HRMS (ESI): m/z 
calcd for C51H71N2O5Si [M + H]+: 847.4902; found: 847.4904. 
4.20.2 Synthesis of 6-(Benzyloxy)-2'-((S)-1-(((3R,4R,E)-4,7-bis((tert-butyldimethylsilyl)oxy)-1-
phenylhept-1-en-3-yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (29b) 
TBS ether 29b was prepared from compound 28b (105.0 mg, 0.143 mmol) according to the 
General Method for the Silylation of a Secondary Alcohol. Purification by column chromatography 
on silica gel eluting with 10:90 EtOAc/hexanes gave the title compound 29b as a pale yellow oil (89.4 
mg, 85%). 1H NMR analysis revealed the presence of two biphenyl axis rotamers in a 55:45 ratio. Rf = 
0.56 (EtOAc:hexanes = 30:70). IR (neat): νmax 2926, 2856, 2225, 1600, 1513, 1490, 1361, 1155, 1035, 
834, 744, 693 cm-1. [𝛼]𝐷
25  - 36 (c 0.18, CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal 
of the minor rotamer, CDCl3): δ 7.43 – 7.09 (m, 11.1H, H-2, H-4 and ArH), 7.00* (d, J = 7.5 Hz, 
0.9H, ArH), 6.84 (d, J = 8.5 Hz, 0.55H, H-5), 6.66* (d, J = 8.7 Hz, 0.45H, H-5), 6.63* (s, 0.45H, H-
6′), 6.55 (s, 0.55H, H-6′), 5.96 (d, J = 16.1 Hz, 0.55H, H-1′′′), 5.93 – 5.85 (m, 1H, H-1′′′ and H-2′′′), 
5.71* (dd, J = 16.0, 7.1 Hz, 0.45H, H-2′′′), 5.72* – 5.64* (m, 0.45H, H-3′′), 5.63 – 5.50 (m, 0.55H, H-
3′′), 5.13* (d, J = 16.1 Hz, 0.9H, H-4′′), 5.10 – 4.95 (m, 2.2H, H-4′′ and PhCH2O), 4.87* (s, 0.90H, 
PhCH2O), 3.96* (s, 1.35H, OCH3), 3.95 (s, 2.65H OCH3), 3.85 (s, 2.65H OCH3), 3.77* (s, 1.35H 
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OCH3), 3.61* (dd, J = 9.5, 3.7 Hz, 0.45H, H-1′′), 3.58 – 3.42 (m, 3.55H, H-1′′, H-4′′′ and H-7′′′), 2.86 
– 2.77 (m, 1H, H-3′′′), 2.43 – 2.22 (m, 1.45H, H-2′′ (minor) and H-2′′A), 2.12 (dt, J = 13.9, 9.2 Hz, 
0.55H, H-2′′B), 1.84 (br s, 1H, NH), 1.76 – 1.67 (m, 1.1H, H-5′′′), 1.53* – 1.45* (m, 0.9H, H-5′′′), 
1.43 – 1.27 (m, 2H, H-6′′′), 0.89 – 0.85 (m, 13.95H, (CH3)3CSi)), 0.82* (s, 4.05H, (CH3)3CSi)), 0.01 
(s, 6.3H, CH3Si), -0.01 (s, 1.65H, CH3Si), -0.05* (s, 1.35H, CH3Si), -0.08* (s, 1.35H, CH3Si), -0.16* 
(s, 1.35H, CH3Si). 13C NMR (125 MHz, the asterisk* denotes the signal of the minor rotamer, 
CDCl3): δ 159.7 (C-6), 159.1* (C-6), 149.2* (C-4′), 149.1 (C-4′), 147.3 (C-5′), 147.1* (C-5′), 137.5* 
(ArC), 136.9 (ArC), 136.3 (C-3′′), 136.1* (C-2), 135.8 (C-2), 135.7 (ArC), 135.7* (C-3′′), 135.4* (C-
2′), 135.2 (C-2′), 133.2 (C-4), 133.0* (C-4), 132.7* (C-2′′′), 132.1 (C-1), 131.4* (C-1), 131.3 (C-2′′′), 
130.9 (C-1′′′), 130.2* (C-1′′′), 128.7* (0.9 x ArCH), 128.7 (1.1 x ArCH), 128.7 (1.1 x ArCH), 128.5* 
(0.9 x ArCH), 128.1 (0.55 x ArCH), 128.0* (0.45 x ArCH), 127.9 (C-1′), 127.4* (C-1′), 127.3 (0.55 x 
ArCH), 127.1* (0.45 x ArCH), 126.8 (1.1 x ArCH), 126.2 (2 x ArCH), 126.0* (0.9 x ArCH), 119.2* 
(C≡N), 118.9 (C≡N), 118.1* (C-4′′), 117.4 (C-4′′), 113.1* (C-6′), 112.9* (C-5), 112.8 (C-6′), 112.7 
(C-5), 109.8 (C-3′), 109.6* (C-3′), 104.2 (C-3), 103.5* (C-3), 76.4* (C-4′′′), 76.2 (C-4′′′), 70.4 
(PhCH2O), 69.9* (PhCH2O), 63.3 (C-7′′′), 63.2* (C-7′′′), 60.0 (C-3′′′), 59.2* (C-3′′′), 56.1* (OCH3), 
56.0 (OCH3), 54.1 (C-1′′), 54.0* (C-1′′), 44.0* (C-2′′), 42.4 (C-2′′), 30.2* (C-5′′′), 30.2 (C-5′′′), 29.0* 
(C-6′′′), 28.9 (C-6′′′), 26.1 ((CH3)3CSi), 26.1* ((CH3)3CSi), 26.0* ((CH3)3CSi), 18.4 ((CH3)3CSi), 
18.2* ((CH3)3CSi), 18.2* ((CH3)3CSi), -4.1* (CH3Si), -4.1* (CH3Si), -4.5 (CH3Si), -5.2 (CH3Si). 
HRMS (ESI): m/z calcd for C51H71N2O5Si2 [M + H]+: 847.4902; found: 847.4935. 
4.21 General Method for the Selective Deprotection of a Primary TBS Ether 
4.21.1 Synthesis of 6-(Benzyloxy)-2'-((S)-1-(((3R,4R,E)-4-((tert-butyldimethylsilyl)oxy)-7-hydroxy-1-
phenylhept-1-en-3-yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (30a) 
A solution of bis-silyl ether 29a (72.40 g, 0.085 mmol, 1.0 equiv) in anhydrous THF (0.85 
mL) in a plastic vial was cooled at 0 °C. HF·py solution, which was prepared from 2.00 g of 70% 
HF·pyridine, 4 mL of pyridine and 16 mL of THF, (1.46 mL, 1.025 mmol, 12.0 equiv) was added in 
one portion and the mixture was stirred at 0 °C for 4 h and then quenched by careful addition of sat. 
aqueous NaHCO3 solution. The aqueous layer was extracted with EtOAc (3 x 5 mL). The combined 
organic layer was dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified 
by column chromatography on silica gel eluting with 0:100 to 4:96 MeOH/CH2Cl2 to afford the title 
compound 30a as a pale yellow oil (49.4 mg, 79%). 1H NMR analysis revealed the presence of two 
biphenyl axis rotamers in a 60:40 ratio. Rf = 0.37 (MeOH:CH2Cl2 = 3:97). IR (neat): νmax 3519, 2929, 
2224, 1600, 1515, 1250, 1035, 694 cm-1. [𝛼]𝐷
25 + 36 (c 0.74, CHCl3). 1H NMR (500 MHz, the 
asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.44* (dd, J = 8.6, 2.1 Hz, 0.4H, H-4), 
7.38* (d, J = 2.1 Hz, 0.4H, H-2), 7.35 (d, J = 2.1 Hz, 0.6H, H-2), 7.34 – 7.03 (m, 11.6H, H-4, H-3′ 
and ArH), 6.89 (d, J = 8.6 Hz, 0.6H, H-5), 6.55* (s, 0.4H, H-6′), 6.51* (d, J = 9.1 Hz, 0.4H, H-5), 
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6.49 (s, 0.6H, H-6′), 6.22 (d, J = 16.0 Hz, 0.6H, H-1′′′), 6.09* (d, J = 16.0 Hz, 0.4H, H-1′′′), 5.71* (dd, 
J = 16.0, 9.1 Hz, 0.4H, H-2′′′), 5.64 (dd, J = 16.0, 8.6 Hz, 0.6H, H-2′′′), 5.60 – 5.48 (m, 1H, H-3′′), 
5.09 – 5.00 (m, 1.2H, PhCH2O), 5.00 – 4.79 (m, 2.8H, H-4′′ and PhCH2O), 3.95 (s, 1.8H, OCH3), 
3.92* (s, 1.2H, OCH3), 3.81* (s, 1.2H, OCH3), 3.77 (s, 1.8H, OCH3), 3.65 – 3.52 (m, 3.4H, H-1′′, H-
4′′′ and H-7′′′), 3.45 (t, J = 6.5 Hz, 0.6H, H-1′′), 3.22 (dd, J = 8.8, 3.4 Hz, 0.6H, H-3′′′), 3.11* (dd, J = 
9.1, 4.2 Hz, 0.4H, H-3′′′), 2.46 – 2.25 (m, 2H, H-2′′), 1.83 (s, 2H, OH and NH), 1.71 – 1.39 (m, 4H, 
H-5′′′ and H-6′′′), 0.88 (s, 5.4H, (CH3)3CSi), 0.80* (s, 3.6H, (CH3)3CSi), 0.06 (s, 1.8H, CH3Si), 0.04* 
(s, 1.2H, CH3Si), 0.01 (s, 1.8H, CH3Si), -0.01* (s, 1.2H, CH3Si). 13C NMR (125 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 159.6 (C-6), 159.0* (C-6), 149.0* (C-4′), 148.9 (C-
4′), 147.3 (C-5′), 137.3* (ArC), 136.9 (ArC), 136.1* (ArC), 136.0 (C-3′′), 135.8 (ArC), 135.7* (C-3′′), 
135.67 (C-2′), 135.5 (C-2), 135.2* (C-2), 135.1* (C-2′), 133.1 (C-4), 132.9* (C-4), 132.1* (C-1′′′), 
132.0 (C-1), 131.9* (C-1), 131.3 (C-1′′′), 130.4 (C-2′′′), 129.3 (C-2′′′), 128.7* (0.8 x ArCH), 128.69 
(1.2 x ArCH), 128.6 (1.2 x ArCH), 128.5* (0.8 x ArCH), 128.1 (0.6 x ArCH), 128.09* (0.4 x ArCH), 
127.6 (C-1′), 127.5* (C-1′), 127.4 (ArCH), 126.7 (1.2 x ArCH), 126.5* (1.6 x ArCH), 126.4 (1.2 x 
ArCH), 119.2 (C≡N), 119.16* (C≡N), 117.4* (C-4′′), 117.3 (C-4′′), 113.2* (C-5), 112.9 (C-5), 112.7* 
(C-6′), 112.4 (C-6′), 110.4 (C-3′), 110.3* (C-3′), 103.8 (C-3), 103.7* (C-3), 75.9 (C-4′′′), 75.4* (C-
4′′′), 70.3 (PhCH2O), 70.1* (PhCH2O), 64.7 (C-3′′′), 63.1 (C-7′′′), 62.9* (C-7′′′), 61.9* (C-3′′′), 56.6 
(C-1′′), 56.1 (OCH3), 56.03 (OCH3), 56.0* (OCH3), 55.96* (OCH3), 55.4* (C-1′′), 41.1 (C-2′′), 40.8* 
(C-2′′), 30.8* (C-6′′′), 29.4 (C-6′′′), 29.2 (C-5′′′), 28.4* (C-5′′′), 26.1 ((CH3)3CSi), 26.0* ((CH3)3CSi), 
18.2 ((CH3)3CSi), 18.18* ((CH3)3CSi), -4.0* (CH3Si), -4.1 (CH3Si), -4.2* (CH3Si). HRMS (ESI): m/z 
calcd for C45H57N2O5Si [M + H]+: 733.4037; found: 733.4057. 
4.21.2 Synthesis of 6-(Benzyloxy)-2'-((S)-1-(((3S,4R,E)-4-((tert-butyldimethylsilyl)oxy)-7-hydroxy-1-
phenylhept-1-en-3-yl)amino)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (30b) 
Diol 30b was prepared from compound 29b (55.9 mg, 0.066 mmol) according to General 
Method for the Selective Deprotection of a Primary TBS Ether. The crude product was purified by 
column chromatography on silica gel eluting with 0:100 to 1:99 MeOH/CH2Cl2 to afford the title 
compound 30b as a pale yellow oil (37.1 mg, 77%). 1H NMR analysis revealed the presence of two 
biphenyl axis rotamers in a 54:46 ratio. Rf = 0.37 (MeOH:CH2Cl2 = 3:97). IR (neat): νmax 3519, 2930, 
2224, 1599, 1513, 1490, 1248, 1153,1035, 734, 745, 694 cm-1. [𝛼]𝐷
25 - 64 (c 0.51, CHCl3). 1H NMR 
(500 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.42 – 7.38 (m, 1.46H, H-
2 and H-4), 7.36 (dd, J = 8.6, 2.1 Hz, 0.54H, H-4), 7.34 – 7.19 (m, 8.16H, ArH), 7.18 – 7.11 (m, 
1.92H, H-3′ and ArH), 7.02* (d, J = 6.9 Hz, 0.92H, ArH), 6.86 (d, J = 8.6 Hz, 0.54H, H-5), 6.71* (d, 
J = 9.2 Hz, 0.46H, H-5), 6.65* (s, 0.46H, H-6′), 6.57 (s, 0.54H, H-6′), 5.95 (d, J = 16.1 Hz, 0.54H, H-
1′′′), 5.92 – 5.85 (m, 1H, H-1′′′ and H-2′′′), 5.72* (dd, J = 16.0, 7.1 Hz, 0.46H, H-2′′′), 5.72 – 5.49 (m, 
1H, H-3′′), 5.18* – 5.09* (m, 0.92H, H-4′′), 5.08 – 5.02 (m, 1.08H, PhCH2O), 5.02 – 4.96 (m, 1.08H, 
H-4′′), 4.95* – 4.86* (m, 0.92H, PhCH2O), 3.98* (s, 1.38H, OCH3), 3.97 (s, 1.62H, OCH3), 3.86 (s, 
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1.62H, OCH3), 3.79* (s, 1.38H, OCH3), 3.62 – 3.54 (m, 2H, H-1′′ (minor), H-4′′′ (minor) and H-7′′′), 
3.53 – 3.42 (m, 2H, H-1′′, H-4′′′ and H-7′′′ (minor)), 2.84 (dd, J = 7.3, 3.8 Hz, 0.54H, H-3′′′), 2.81* 
(dd, J = 6.9, 2.9 Hz, 0.46H, H-3′′′), 2.45 – 2.25 (m, 1.54H, H-2′′ and H-2′′A), 2.17* (dt, J = 14.0, 9.3 
Hz, 0.46H, H-2′′B), 1.55 – 1.18 (m, 4H, H-5′′′ and H-6′′′), 0.87 (s, 4.86H, (CH3)3CSi), 0.83* (s, 4.14H, 
(CH3)3CSi), -0.00 (s, 1.62H, CH3Si), -0.04* (s, 1.38H, CH3Si), -0.08 (s, 1.62H, CH3Si), -0.16* (s, 
1.38H, CH3Si). 13C NMR (125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 
159.7 (C-6), 159.1* (C-6), 149.2 (C-4′), 149.15* (C-4′), 147.5 (C-5′), 147.2* (C-5′), 137.4* (ArC), 
136.9 (ArC), 136.3 (C-3′′), 136.1* (C-2′), 135.8 (C-2′), 135.7 (ArC), 135.67* (ArC), 135.6 (C-3′′), 
135.4* (C-2), 135.3 (C-2), 133.3 (C-5), 133.1* (C-5), 132.4* (C-2′′′), 132.2 (C-1), 131.3* (C-1), 
131.1 (C-4′′′), 131.0* (C-4′′′), 130.2 (C-2′′′), 128.8* (0.92 x ArCH), 128.7 (1.08 x ArCH), 128.69 
(1.08 x ArCH), 128.5* (0.92 x ArCH), 128.2 (0.54 x ArCH), 128.1* (0.46 x ArCH), 128.0 (C-1′), 
127.8* (C-1′), 127.4 (0.54 x ArCH), 127.2* (0.46 x ArCH), 126.8 (1.08 x ArCH), 126.4* (0.92 x 
ArCH), 126.3 (1.08 x ArCH), 126.1* (0.92 x ArCH), 119.2* (C≡N), 119.0 (C≡N), 118.2* (C-4′′), 
117.5 (C-4′′), 113.1* (C-6′), 112.8 (C-6′), 112.79 (C-5), 110.2* (C-3′), 110.1 (C-3′), 104.2 (C-3), 
103.6* (C-3), 76.2* (C-4′′′), 75.9 (C-4′′′), 70.4 (PhCH2O), 69.9* (PhCH2O), 63.2 (C-7′′′), 63.1* (C-
7′′′), 60.3 (C-3′′′), 59.1* (C-3′′′), 56.3* (OCH3), 56.2 (OCH3), 56.1 (OCH3), 56.05* (OCH3), 54.4 (C-
1′′), 54.1* (C-1′′), 43.8* (C-2′′), 42.3 (C-2′′), 30.4* (C-6′′′), 30.2 (C-6′′′), 28.9* (C-5′′′), 28.8 (C-5′′′), 
26.03 ((CH3)3CSi), 26.0* ((CH3)3CSi), 18.2 ((CH3)3CSi), 18.16* ((CH3)3CSi), -4.08 (CH3Si), -4.1* 
(CH3Si), -4.48* (CH3Si), -4.5 (CH3Si). HRMS (ESI): m/z calcd for C45H57N2O5Si [M + H]+: 
733.4037; found: 733.4037. 
4.22 Synthesis of 6-(Benzyloxy)-2'-((S)-1-((2S,3R)-3-((tert-butyldimethylsilyl)oxy)-2-((E)-
styryl)piperidin-1-yl)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (31a) 
Piperidine 31a was prepared from compound 30a (0.655 g, 0.89 mmol) according to General 
Method for Mesylation-Cyclization. Purification by column chromatography on silica gel eluting with 
15:85 EtOAc/hexanes gave the title compound 31a as a pale yellow oil (0.573 g, 90%). 1H NMR 
analysis revealed the presence of two biphenyl axis rotamers in a 88:12 ratio. Rf = 0.29 
(EtOAc:hexanes = 20:80). IR (neat): νmax 2925, 2852, 2223, 1599, 1516, 1491, 1094, 835, 747, 694 
cm-1. [𝛼]𝐷
25  - 29 (c 2.4, CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal of the minor 
rotamer, CDCl3): δ 7.68 (dd, J = 8.5, 2.2 Hz, 1H, H-4), 7.55 (d, J = 2.2 Hz, 1H, H-2), 7.43 – 7.10 (m, 
8H, ArH), 7.09* (s, 0.12H, H-5), 6.96* (s, 0.12H, H-3′), 6.85 (s, 0.88H, H-3′), 6.83 – 6.78 (m, 2H, 
ArH), 6.81 (d, J = 8.7 Hz, 0.88H, H-5), 6.66* (s, 0.12H , H-6′), 6.61 (s, 0.88H, H-6′), 6.44 (d, J = 15.9 
Hz, 1H, H-2′′′′), 5.66* – 5.53* (m, 0.12H, H-3′′), 5.32 – 5.21 (m, 0.88H, H-3′′), 5.16* (d, J = 12.4 Hz, 
0.12H, PhCHAHBO), 5.08* (d, J = 12.4 Hz, 0.12H, PhCHAHBO), 4.92* (t, J = 17.0, 13.6 Hz, 0.12H, 
H-4′′A), 4.85 (d, J = 17.0 Hz, 0.88H, H-4′′A), 4.73* (dd, J = 15.9, 9.4 Hz, 0.12H, H-4′′B), 4.57 (d, J = 
12.4 Hz, 0.88H, PhCH2O), 4.53 (d, J = 10.2 Hz, 0.88H, H-4′′B), 4.45 (d, J = 12.4 Hz, 0.88H, 
PhCH2O), 4.48 – 4.41 (m, 1H, H-1′′′), 3.92* (s, 0.36H, OCH3), 3.91 (s, 2.64H, OCH3), 3.84 (s, 2.64H, 
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OCH3), 3.80* (s, 0.36H, OCH3), 3.78 (dd, J = 11.5, 3.4 Hz, 1H, H-1′′), 3.15 – 3.06 (m, 1.76H, H-3′′′), 
2.95* – 2.88* (m, 0.24H, H-3′′′), 2.77 (t, J = 8.7 Hz, 1H, H-2′′′), 2.63 – 2.56 (m, 1H, H-6′′′A), 2.56 – 
2.49 (m, 1H, H-2′′A), 2.48 – 2.38 (m, 1H, H-2′′B), 2.06 – 2.00 (m, 1H, H-6′′′B), 1.95 – 1.90 (m, 1H, H-
4′′′A), 1.54 – 1.49 (m, 1H, H-5′′′A), 1.27 – 1.19 (m, 2H, H-4′′′B and H-5′′′B), 0.75 (s, 9H, (CH3)3CSi), 
0.01 (s, 2.64H, CH3Si), -0.09* (s, 0.36H, CH3Si), -0.10 (s, 2.64H, CH3Si), -0.20* (s, 0.36H, CH3Si). 
13C NMR (125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 160.6* (C-6), 
159.1 (C-6), 147.6* (C-4′), 147.4 (C-4′), 147.3 (C-5′), 147.1* (C-5′), 137.8 (C-2), 137.4 (ArC), 136.8* 
(ArC), 136.2 (C-3′′), 136.1* (ArC), 135.9 (ArC), 133.5 9 (C-2′′′′), 133.3* 9 (C-2′′′′), 132.5 (C-1), 
132.4 (C-4), 131.7* (C-1′), 131.4 (C-1′), 131.3 (C-2′), 130.9 (C-1′′′′), 130.4* (C-2′), 128.9* (0.24 x 
ArCH), 128.7* (0.24 x ArCH), 128.4 (3.52 x ArCH), 128.1* (0.12 x ArCH), 127.8 (0.88 x ArCH), 
127.5* (0.12 x ArCH), 127.4 (0.88 x ArCH), 126.8 (1.76 x ArCH), 126.5 (2 x ArCH), 126.3* (0.24 x 
ArCH), 119.4 (C≡N), 119.1* (C≡N), 116.8* (C-4′′), 116.1 (C-4′′), 114.2* (C-6′), 113.8 (C-6′), 113.1 
(C-5), 112.6* (C-5), 112.5* (C-3′), 112.2 (C-3′), 104.0* (C-3), 103.5 (C-3), 72.4 (C-3′′′), 72.3* (C-
3′′′), 71.3* (C-2′′′), 71.1 (C-2′′′), 70.1* (PhCH2O), 69.9 (PhCH2O), 59.6 (C-1′′), 56.2 (OCH3), 56.0 
(OCH3), 44.6* (C-6′′′), 44.3* (C-6′′′), 34.8 (C-4′′′), 34.4* (C-4′′′), 27.0* (C-2′′), 26.1 (C-2′′), 25.9 
((CH3)3CSi), 24.1 (C-5′′′), 23.4* (C-5′′′), 18.1* ((CH3)3CSi), 18.0 ((CH3)3CSi), -4.3 (CH3Si), -4.4 
(CH3Si). HRMS (ESI): m/z calcd for C45H55N2O4Si [M + H]+: 715.3931; found: 715.3958. 
4.23 Synthesis of 6-(Benzyloxy)-2'-((S)-1-((2R,3R)-3-((tert-butyldimethylsilyl)oxy)-2-((E)-
styryl)piperidin-1-yl)but-3-en-1-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (31b) 
Piperidine 31b was prepared from compound 30b (0.489 g, 0.667 mmol) according to 
General Method for Mesylation-Cyclization. Purification by column chromatography on silica gel 
eluting with 10:90 EtOAc/hexanes gave the title compound 31b as a pale yellow oil (0.410 g, 86%). 
1H NMR analysis revealed the presence of two biphenyl axis rotamers in a 51:49 ratio. Rf = 0.50 
(EtOAc:hexanes = 30:70). IR (neat): νmax 2925, 2857, 2218, 1599, 1508, 1489, 1251, 1023, 834, 773 
cm-1. [𝛼]𝐷
25  - 46 (c 0.23, CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal of the minor 
rotamer, CDCl3): δ 7.54 – 7.41 (m, 2H, H-2 and H-4), 7.35 – 7.09 (m, 9.51H, H-3′ and ArH), 7.02 (s, 
0.51H, H-3′), 6.97* (d, J = 7.2 Hz, 0.98H, ArH), 6.92* (d, J = 8.5 Hz, 0.49H, H-5), 6.70* (s, 0.49H, 
H-6′), 6.64 (d, J = 8.5 Hz, 0.51H, H-5), 6.56 (s, 0.51H, H-6′), 6.29* (dd, J = 16.0, 8.4 Hz, 0.49H, H-
1′′′), 6.19 – 6.03 (m, 1.51H, H-1′′′ and H-2′′′), 5.82 – 5.70 (m, 0.51H, H-3′′), 5.70* – 5.60* (m, 0.49H, 
H-3′′), 5.13 – 4.94 (m, 2H, H-4′′ and PhCH2O), 4.82* (d, J = 12.2 Hz, 0.49H, PhCHAHBO), 4.79 – 
4.62 (m, 1.51H, H-4′′and PhCHAHBO), 3.93* (s, 1.47H, OCH3), 3.84 (s, 3.06H, OCH3), 3.81* – 3.76* 
(m, 0.49H, H-1′′), 3.72* (s, 1.47H, OCH3), 3.72 – 3.67 (m, 0.51H, H-1′′), 3.67 – 3.60 (m, 1H, H-3′′′), 
3.20 – 3.17 (m, 0.51H, H-2′′′), 3.17* – 3.11* (m, 0.49H, H-2′′′), 2.81* – 2.73* (m, 0.49H, H-6′′′A), 
2.62 – 2.36 (m, 3.51H, H-2′′, H-6′′′ (major) and H-6′′′B), 1.74 – 1.31 (m, 4H, H-5′′′ and H-6′′′), 0.80 (s, 
4.59H, (CH3)3CSi), 0.75* (s, 4.41H, (CH3)3CSi), -0.03* (s, 1.47H, CH3Si), -0.08 (s, 1.53H, CH3Si), -
0.11 (s, 1.53H, CH3Si), -0.18* (s, 1.47H, CH3Si). 13C NMR (125 MHz, the asterisk* denotes the 
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signal of the minor rotamer, CDCl3): δ 159.3* (C-6), 159.2 (C-6), 148.7* (C-4′), 148.0 (C-4′), 147.1* 
(C-5′), 146.8 (C-5′), 138.2 (ArC), 137.6* (ArC), 136.4* (C-3′′), 136.1 (ArC), 136.0 (C-3′′), 135.7 (C-
2), 134.2* (C-2′), 134.0 (C-2′′′), 133.7 (C-2′), 133.3* (C-2′′′), 133.0* (C-4), 132.8 (C-4), 132.6 (C-1), 
130.9* (C-1), 128.7*  (0.98 x ArCH), 128.68 (2.04 x ArCH), 128.3* (0.98 x ArCH), 128.1 (0.51 x 
ArCH), 128.0* (0.49 x ArCH), 127.3 (C-1′), 127.2 (0.51 x ArCH), 127.0* (0.49 x ArCH), 126.8* 
(0.98 x ArCH), 126.7 (C-1′′′′), 126.3* (0.98 x ArCH), 126.26 (1.02 x ArCH), 126.2 (1.02 x ArCH), 
124.8 (C-1′′′′), 119.3* (C≡N), 118.9 (C≡N), 117.3* (C-4′′), 116.0 (C-4′′), 113.8 (C-6′), 113.6* (C-6′), 
113.0* (C-5), 112.8 (C-5), 111.3 (C-3′), 110.8* (C-3′), 104.2 (C-3), 103.2* (C-3), 71.8 (C-3′′′), 71.6* 
(C-3′′′), 70.4 (PhCH2O), 69.8* (PhCH2O), 65.3 (C-2′′′), 62.9* (C-2′′′), 61.4 (C-1′′), 59.9* (C-1′′), 
56.1* (OCH3), 56.0* (OCH3), 55.9 (OCH3), 43.3* (C-6′′′), 42.2 (C-6′′′), 39.7 (C-2′′), 36.4* (C-2′′), 
30.4* (C-4′′′), 29.7 (C-4′′′), 26.0 ((CH3)3CSi), 24.5 (C-5′′′), 23.9* (C-5′′′), 18.2 ((CH3)3CSi), -4.4* 
(CH3Si), -4.48 (CH3Si), -4.5 (CH3Si), -4.7* (CH3Si). HRMS (ESI): m/z calculated for C45H55N2O4Si 
[M + H]+: 715.3944; found: 715.3940. 
4.24 Synthesis of 6-(Benzyloxy)-2'-((1R,6S,9aS)-1-((tert-butyldimethylsilyl)oxy)-1,3,4,6,7,9a-
hexahydro-2H-quinolizin-6-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (32a) 
Quinolizidine 32a was prepared from compound 31a (71.5 mg, 0.1 mmol) according to 
General Method for Ring-Closing Metathesis, using Grubbs’ II Ru catalyst (8.5 mg, 0.001 mmol, 0.1 
equiv). Purification by column chromatography on silica gel eluting with 20:80 EtOAc/hexanes gave 
the title compound 32a as a light brown oil (43.0 mg, 70%). 1H NMR analysis revealed the presence 
of two biphenyl axis rotamers in a 76:24 ratio. Rf = 0.22 (EtOAc:hexanes = 30:70). IR (neat): νmax 
2923, 2853, 2229, 1600, 1515, 1463, 1252, 836, 775, 696 cm-1. [𝛼]𝐷
25  + 7.7 (c 2.2, CHCl3). 1H NMR 
(500 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.61* (d, J = 8.9 Hz, 
0.24H, H-4), 7.58 (dd, J = 8.5, 2.2 Hz, 0.76H, H-4), 7.53 (d, J = 2.2 Hz, 0.76H, H-2), 7.34 – 7.25 (m, 
4.24H, H-2 and ArH), 7.22* (d, J = 7.3 Hz, 0.48H, ArH), 7.17 (d, J = 6.1 Hz, 1.52H, ArH), 7.14* (s, 
0.24H, H-3′), 7.11 (s, 0.76H, H-3′), 7.08* (d, J = 8.6 Hz, 0.24H, H-5), 6.97 (d, J = 8.6 Hz, 0.76H, H-
5), 6.70* (s, 0.24H, H-6′), 6.57 (s, 0.76H, H-6′), 6.11 (d, J = 10.0 Hz, 1H, H-9′′), 5.96* (d, J = 9.7 Hz, 
0.24H, H-8′′), 5.86 (d, J = 10.0 Hz, 0.76H, H-8′′), 5.17* (d, J = 12.2 Hz, 0.24H, PhCHAHBO (minor)), 
5.12 – 5.01 (m, 1.76H, PhCHAHBO (minor) and PhCH2O), 4.03* (d, J = 6.1 Hz, 0.24H, H-6′′), 3.88 (s, 
2.28H, OCH3), 3.85* (s, 0.72H, OCH3), 3.83 (s, 2.28H, OCH3), 3.82 – 3.78 (m, 0.76H, H-6′′), 3.78* 
(s, 0.72H, OCH3), 3.34 – 3.20 (m, 1H, H-1′′), 2.80 – 2.55 (m, 2H, H-7′′A (minor), H-7′′A and H-9a′′), 
2.27* (d, J = 17.1 Hz, 0.24H, H-7′′B (minor)), 2.10 – 1.91 (m, 1.76H), H-4′′A and H-7′′B), 1.85 (dd, J = 
12.8, 3.8 Hz, 1H, H-2′′A), 1.78 (td, J = 11.8, 3.0 Hz, 1H, H-4′′B), 1.50 – 1.29 (m, 2H, H-3′′), 1.20 – 
1.08 (m, 1H, H-2′′B), 0.88 (s, 9H, (CH3)3CSi), 0.05 (s, 2.28H, CH3Si), 0.03 (s, 2.28H, CH3Si), 0.01* 
(s, 0.72H, CH3Si), 0.00* (s, 0.72H, CH3Si). 13C NMR (125 MHz, the asterisk* denotes the signal of 
the minor rotamer, CDCl3): δ 159.5* (C-6), 159.4 (C-6), 148.9 (C-4′), 147.5 (C-5′), 146.9* (C-5′), 
135.9* (C-2), 135.89* (ArC), 135.8 (ArC), 135.7 (C-2), 133.2 (C-4), 133.17 (C-1), 132.6 (C-2′), 
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132.3* (C-1), 131.8* (C-2′), 128.8* (0.48 x ArCH), 128.77 (1.52 x ArCH), 128.6 (C-1′), 128.5* (C-
1′), 128.3 (0.76 x ArCH), 128.2* (0.24 x ArCH), 127.6* (C-9′′), 127.4 (C-9′′), 127.0 (1.52 x ArCH), 
126.6* (0.48 x ArCH), 125.3 (C-8′′), 124.8* (C-8′′), 119.2 (C≡N), 119.1* (C≡N), 113.2* (C-5), 
113.1* (C-6′), 112.9 (C-5), 112.7 (C-6′), 110.6* (C-3′), 110.4 (C-3′), 104.5 (C-3), 104.0* (C-3), 72.6 
(C-1′′), 72.4* (C-1′′), 70.8 (PhCH2O), 70.3* (PhCH2O), 61.7* (C-9a′′), 61.3 (C-9a′′), 56.3 (C-6′′), 56.0 
(OCH3), 55.95* (OCH3), 55.9 (OCH3), 54.8* (C-6′′), 51.4 (C-4′′), 50.7* (C-4′′), 35.1* (C-2′′), 34.9 
(C-2′′), 32.7* (C-7′′), 32.0 (C-7′′), 26.0 ((CH3)3CSi), 23.7 (C-3′′), 23.3* (C-3′′), 18.2 ((CH3)3CSi), -3.8 
(CH3Si), -3.9* (CH3Si), -4.5* (CH3Si), -4.6 (CH3Si). HRMS (ESI): m/z calcd for C37H47N2O4Si [M + 
H]+: 611.3305; found: 611.3324. 
4.25 Synthesis of 6-(Benzyloxy)-2'-((1R,6S,9aR)-1-((tert-butyldimethylsilyl)oxy)-1,3,4,6,7,9a-
hexahydro-2H-quinolizin-6-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (32b) 
Quinolizidine 32b was prepared from compound 31b (190.2 mg, 0.2660 mmol) according to 
General Method for Ring-Closing Metathesis, using Grubbs’ II Ru catalyst (33.9 mg, 0.0399 mmol, 
0.15 equiv). The crude product was purified by column chromatography on silica gel eluting with 
2:98 MeOH/CH2Cl2 to afford the title compound 32b as a light brown oil (109.2 mg, 67%). 1H NMR 
analysis revealed the presence of two biphenyl axis rotamers in a 56:44 ratio. Rf = 0.27 
(EtOAc:hexanes = 20:80). IR (neat): νmax 2925, 2853, 2224, 1601, 1516, 1252, 1034, 834, 772, 735, 
695 cm-1. [𝛼]𝐷
25  + 33 (c 0.17, CHCl3) 1H NMR (500 MHz, the asterisk* denotes the signal of the 
minor rotamer, CDCl3): δ 7.59* (d, J = 8.6 Hz, 0.44H, H-4), 7.56 (d, J = 8.6 Hz, 0.56H, H-4), 7.42* 
(s, 0.44H, H-2), 7.38 (s, 0.56H, H-2), 7.32 – 7.15 (m, 6H, H-3 and ArH), 7.02* (d, J = 8.6 Hz, 0.44H, 
H-5), 6.99 (d, J = 8.6 Hz, 0.56H, H-5), 6.57 (s, 0.56H, H-6′), 6.55 (s, 0.44H, H-6′), 5.69 – 5.59 (m, 
1H, H-8′′), 5.39 (d, J = 10.2 Hz, 0.56H, H-9′′), 5.35* (d, J = 10.3 Hz, 0.44H, H-9′′), 5.18 – 5.05 (m, 
2H, PhCH2O), 3.91 (s, 1.68H, OCH3), 3.90* (s, 1.32H, OCH3), 3.84 (s, 1.68H, OCH3), 3.83* (s, 
1.32H, OCH3), 3.79 – 3.71 (m, 1H, H-1′′), 3.18 (s, 0.56H, H-6′′), 3.04* (s, 0.44H, H-6′′), 2.74 – 2.57 
(m, 3H, H-4′′ and H-9a′′ ), 2.35* – 2.16* (m, 0.88H, H-7′′), 2.04 – 1.89 (m, 1.12H, H-7′′), 1.85 – 1.58 
(m, 2H, H-2′′ and H-3′′), 1.49* – 1.36* (m, 0.88H, H-2′′), 1.35 – 1.21 (m, 1.22H, H-3′′), 0.91 (s, 9H, 
(CH3)3CSi)), 0.03* (s, 1.32H, CH3Si), 0.02 (s, 1.68H, CH3Si), 0.01 (s, 3H, CH3Si). 13C NMR (125 
MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 159.8* (C-6), 159.3 (C-6), 
149.5* (C-4′), 149.4 (C-4′), 147.3* (C-5′), 147.1 (C-5′), 136.0* (ArC), 135.96 (ArC), 135.9 (C-2), 
135.2* (C-2), 133.3* (C-4), 133.1 (C-4), 132.4 (C-2′), 132.2 (C-1), 128.8 (C-9′′ and 1.12 x ArCH), 
128.7* (0.88 x ArCH), 128.2 (0.56 x ArCH), 128.1* (0.44 x ArCH), 127.6 (C-1′), 126.8* (0.88 x 
ArCH), 126.7 (1.12 x ArCH), 125.3 (C-8′′), 124.9* (C-8′′), 119.4 (C≡N), 119.3* (C≡N), 113.0 (C-5), 
112.8* (C-5), 112.3 (C-6′), 110.1 (C-3′), 109.7* (C-3′), 104.0* (C-3), 103.9 (C-3), 70.4 (PhCH2O), 
70.3* (PhCH2O), 69.8 (C-1′′), 69.76* (C-1′′), 65.9 (C-9a′′), 59.7 (C-6′′), 59.4* (C-6′′), 56.1 (OCH3), 
56.0 (OCH3), 55.9* (OCH3), 55.8* (OCH3), 52.2 (C-4′′), 35.9 (C-7′′), 33.4* (C-2′′), 33.0 (C-2′′), 25.94 
((CH3)3CSi), 25.9* ((CH3)3CSi), 21.8 (C-3′′), 21.5* (C-3′′), 18.32 ((CH3)3CSi), 18.3 ((CH3)3CSi), -
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4.2* (CH3Si), -4.5 (CH3Si). HRMS (ESI): m/z calcd for C37H47N2O4Si [M + H]+: 611.3305; found: 
611.3311. 
4.26 General Method for Reduction of a Nitrile 
4.26.1 Synthesis of 6-(Benzyloxy)-2'-((1R,6S,9aS)-1-((tert-butyldimethylsilyl)oxy)-1,3,4,6,7,9a-
hexahydro-2H-quinolizin-6-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbaldehyde (33a) 
To a solution of carbonitrile 32a (91.6 mg, 0.15 mmol, 1.0 equiv) in toluene (0.54 mL) at -78 
°C was added DIBAL-H (0.3 mL, 0.30 mmol, 1.0 M in toluene, 2.0 equiv). After stirring for 1 h, the 
reaction was quenched with water at -78 °C and allowed to reach room temperature and stirred for 
another 30 min. The reaction mixture was extracted with EtOAc (3 x 2 mL). The combined organic 
layer was dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by 
column chromatography on silica gel eluting with 25:75 EtOAc/CH2Cl2 to afford the title compound 
33a as a pale yellow oil (77.9 mg, 83%). 1H NMR analysis revealed the presence of two biphenyl axis 
rotamers in a 77:23 ratio. Rf = 0.37 (EtOAc:hexanes = 40:60). IR (neat): νmax 2933, 2852, 1692, 1599, 
1515, 1251, 1115, 835, 773 cm-1. [𝛼]𝐷
25  + 8.6 (c 0.34, CHCl3). 1H NMR (500 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 9.93 (s, 0.77H, CHO), 9.90* (s, 0.23H, CHO), 
7.86* (dd, J = 8.5, 2.2 Hz, 0.23H, H-4), 7.82 (dd, J = 8.5, 2.2 Hz, 0.77H, H-4), 7.79 (d, J = 2.2 Hz, 
0.77H, H-2), 7.57* (d, J = 2.2 Hz, 0.23H, H-2), 7.36 – 7.16 (m, 5.23H, H-5 and ArH), 7.15* (s, 
0.23H, H-3′), 7.11 (s, 0.77H, H-3′), 7.04 (d, J = 8.5 Hz, 0.77H, H-5), 6.75* (s, 0.23H, H-6′), 6.64 (s, 
0.77H, H-6′), 6.10 (d, J = 9.8 Hz, 1H, H-9′′), 5.98 – 5.93* (m, 0.23H, H-8′′), 5.89 – 5.84 (m, 0.77H, 
H-8′′), 5.22* (d, J = 12.3 Hz, 0.23H, PhCHAHBO (minor)), 5.17 – 5.03 (m, 1.77H, PhCH2O and 
PhCHAHBO (minor)), 4.12* – 4.07* (m, 0.23H, H-6′′), 3.88 (s, 2.31H, OCH3), 3.86* (s, 0.69H, 
OCH3), 3.83 (s, 3.08H, H-6′′ and OCH3), 3.78* (s, 0.69H, OCH3), 3.31 – 3.18 (m, 1H, H-1′′), 2.78 – 
2.55 (m, 2H, H-7′′A (minor), H-7′′A, H-9a′′), 2.35* – 2.24* (m, 0.23H, H-7′′B (minor)), 2.16 – 1.91 (m, 
1.77H, H-4′′A and H-7′′B), 1.88 – 1.72 (m, 2H, H-2′′A and H-4′′B), 1.42 – 1.29 (m, 2H, H-3′′), 1.21 – 
1.07 (m, 1H, H-2′′B), 0.88 (s, 6.93H, (CH3)3CSi), 0.87* (s, 2.07H, (CH3)3CSi), 0.05 (s, 2.31H, CH3Si), 
0.03* (s, 0.69H, CH3Si), 0.02 (s, 2.31H, CH3Si), -0.00* (s, 0.69H, CH3Si). 13C NMR (125 MHz, the 
asterisk* denotes the signal of the minor rotamer, CDCl3): δ 191.0 (C=O), 190.8* (C=O), 161.1* (C-
6), 161.06 (C-6), 148.7 (C-4′), 147.5 (C-5′), 146.9* (C-5′), 136.2* (ArC), 136.1 (ArC), 134.0* (C-2), 
133.3 (C-2), 132.6 (C-1), 132.5 (C-2′), 132.3* (C-1), 131.7 (C-4), 131.3* (C-4), 130.1 (C-3), 129.6 
(C-1′), 129.5* (C-1′), 128.8 (1.54 x ArCH), 128.7* (0.46 x ArCH), 128.2 (C-1), 127.6* (C-9′′), 127.4 
(C-9′′), 126.9 (1.54 x ArCH), 126.6* (0.46 x ArCH), 125.4 (C-8′′), 124.9* (C-8′′), 113.3* (C-6′), 
112.9 (C-6′), 112.6* (C-5), 112.3 (C-5), 110.6* (C-3′), 110.3 (C-3′), 72.6 (C-1′′), 72.4* (C-1′′), 70.8 
(PhCH2O), 70.3 (PhCH2O), 61.7* (C-9a′′), 61.4 (C-9a′′), 56.2 (C-6′′), 56.0 (OCH3), 55.9 (OCH3), 
54.7* (C-6′′), 51.3 (C-4′′), 50.7* (C-4′′), 35.1* (C-2′′), 34.9 (C-2′′), 32.8* (C-7′′), 32.1 (C-7′′), 26.0 
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((CH3)3CSi), 23.7 (C-3′′), 23.3* (C-3′′), 18.2 ((CH3)3CSi), -3.8 (CH3Si), -3.9* (CH3Si), -4.5 (CH3Si). 
HRMS (ESI): m/z calcd for C37H48NO5Si [M + H]+: 614.3302; found: 614.3313. 
4.26.2 Synthesis of 6-(Benzyloxy)-2'-((1R,6S,9aR)-1-((tert-butyldimethylsilyl)oxy)-1,3,4,6,7,9a-
hexahydro-2H-quinolizin-6-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbaldehyde (33b) 
Aldehyde 33b was prepared from compound 32b (46.0 mg, 0.075 mmol) according to the 
General Method for Reduction of a Nitrile. The crude product was purified by column 
chromatography on silica gel eluting with 15:85 EtOAc/CH2Cl2 to afford the title compound 33b as a 
pale yellow oil (24.8 mg, 54 %). 1H NMR analysis revealed the presence of two biphenyl axis 
rotamers in a 53:47 ratio. Rf = 0.33 (EtOAc:hexanes = 30:70). IR (neat): νmax 2927, 2854, 1691, 1597, 
1251, 1116, 835, 773 cm-1. [𝛼]𝐷
25  + 9.4 (c 0.55, CHCl3). 1H NMR (500 MHz, the asterisk* denotes 
the signal of the minor rotamer, CDCl3): δ 9.94 (s, 0.53H, CHO), 9.93* (s, 0.47H, CHO), 7.87 (dd, J = 
8.7, 2.1 Hz, 0.53H, H-4), 7.85* (dd, J = 8.6, 2.1 Hz, 0.47H, H-4), 7.71* (d, J = 2.1 Hz, 0.47H, H-2), 
7.68 (d, J = 2.1 Hz, 0.53H, H-2), 7.35 – 7.21 (m, 6H, H-3′ and ArH), 7.12* (d, J = 8.6 Hz, 0.47H, H-
5), 7.09 (d, J = 8.7 Hz, 0.53H, H-5), 6.66 (s, 0.53H, H-6′), 6.63* (s, 0.47H, H-6′), 5.66 (br s, 1H, H-
8′′), 5.40* (d, J = 10.5 Hz, 0.47H, H-9′′), 5.36 (d, J = 10.5 Hz, 0.53H, H-9′′), 5.26 – 5.12 (m, 2H, 
PhCH2O), 3.95 (s, 1.59H, OCH3), 3.94* (s, 1.41H, OCH3), 3.87 (s, 3H, OCH3), 3.77 (br s, 1H, H-1′′), 
3.25 (br s, 0.53H, H-6′′), 3.12* (br s, 0.47H, H-6′′), 2.77 – 2.67 (m, 2.53H, H-4′′ and H-9a′′), 2.64 (br 
s, 0.47H, H-9a′′), 2.36* – 2.16* (m, 0.94H, H-7′′), 2.06 – 1.96 (m, 1.06H, H-7′′), 1.94 – 1.40 (m, 4H, 
H-2′′ and H-3′′), 0.94 (s, 9H, (CH3)3CSi), 0.05 (s, 2.82H, CH3Si), 0.04 (s, 3.18H, CH3Si). 13C NMR 
(125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 191.05 (C=O), 191.0* 
(C=O), 161.4 (C-6), 161.0* (C-6), 149.3* (C-4′), 149.3 (C-4′), 147.2* (C-5′), 147.0 (C-5′), 136.6* (C-
2′), 136.3 (ArC), 136.2* (ArC), 135.5 (C-2′), 133.8 (C-2), 133.2* (C-2), 131.8 (C-1), 131.6* (C-1), 
131.5* (C-4), 131.2 (C-4), 129.7* (C-3), 129.7 (C-3), 129.1* (C-1′), 128.7 (1.06 x ArCH), 128.6* 
(0.94 x ArCH), 128.5 (C-1′), 128.1 (0.53 x ArCH), 128.0* (0.47 x ArCH), 126.8* (0.94 x ArCH), 
126.7 (1.06 x ArCH), 125.4 (C-8′′), 125.0* (C-8′′), 112.5* (C-5), 112.5 (C-6′), 112.3 (C-5), 110.0 (C-
3′), 109.6* (C-3′), 70.3 (PhCH2O), 70.3* (PhCH2O), 69.8 (C-1′′), 69.8* (C-1′′), 66.0 (C-9a′′), 65.9* 
(C-9a′′), 59.7 (C-6′′), 59.4* (C-6′′), 56.0 (OCH3), 56.0 (OCH3), 55.9* (OCH3), 55.8* (OCH3), 52.3 (C-
4′′), 35.8 (C-7′′), 33.4* (C-2′′), 33.1 (C-2′′), 25.9 ((CH3)3CSi), 21.8 (C-3′′), 21.5* (C-3′′), 18.3 
((CH3)3CSi), -4.2 (CH3Si), -4.5 (CH3Si). HRMS (ESI): m/z calcd for C37H48NO5Si [M + H]+: 
614.3302; found: 614.3306. 
4.27 General Method for the Still–Gennari Modified Horner-Wadsworth-Emmons Reaction 




 To a solution of 18-crown-6 (66.5 mg, 0.2515 mmol, 5.0 equiv) in anhydrous THF (1.0 mL) 
at -78 °C was added KHMDS (0.15 mL, 0.0755 mmol, 0.5 M in toluene, 1.5 equiv) and the mixture 
was stirred for 10 min. Bis(2,2,2-trifluoro-ethyl)(methoxycarbonylmethyl)phos-phornate (24.0 mg, 
0.0755 mmol, 1.5 equiv) was added and the reaction mixture was strried for 10 min. A solution of 
aldehyde 33a (30.9 mg, 0.0503 mmol, 1.0 equiv) in THF (0.11 mL) was added slowly and stirring 
was continued for 2 h. The reaction was quenched with sat. aqueous NH4Cl solution and extracted 
with EtOAc (3 x 5 mL). The combined organic layer was brine, dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified by column chromatography on silica gel 
eluting with 30:70 EtOAc/hexanes to afford the title compound 34a as a pale yellow oil (20.9 mg, 
60%). 1H NMR analysis revealed the presence of two biphenyl axis rotamers in a 71:29 ratio. Rf = 
0.25 (EtOAc:hexanes = 30:70). IR (neat): νmax 2927, 1723, 1626, 1598, 1515, 1495, 1462, 1250, 1192, 
1169, 1114, 1042, 835, 773, 696 cm-1. [𝛼]𝐷
25  + 30 (c 0.19, CHCl3). 1H NMR (500 MHz, the asterisk* 
denotes the signal of the minor rotamer, CDCl3): δ 7.78* (dd, J = 8.7, 2.3 Hz, 0.29H, H-4′), 7.72 (dd, 
J = 8.5, 2.3 Hz, 0.71H, H-4′), 7.54 (d, J = 2.3 Hz, 0.71H, H-2′), 7.42* (d, J = 2.3 Hz, 0.29H, H-2′), 
7.34 – 7.16 (m, 5H, ArH), 7.15* (s, 0.29H, H-3′′), 7.10 (s, 0.71H, H-3′′), 7.01* (d, J = 8.7 Hz, 0.29H, 
H-5′), 6.93 – 6.81 (m, 1.71H, H-3 and H-5′), 6.79* (s, 0.29H, H-6′′), 6.68 (s, 0.71H, H-6′′), 6.10 (d, J 
= 9.8 Hz, 1H, H-9′′′), 5.96* (d, J = 10.1 Hz, 0.29H, H-8′′′), 5.89 – 5.82 (m, 0.71H, H-8′′′), 5.86 (d, J = 
12.6 Hz, 1H, H-2), 5.15* (d, J = 12.3 Hz, 0.29H, PhCHAHBO (minor)), 5.03 (dd, J = 13.7, 7.1 Hz, 
1.71H, PhCHAHBO (minor) and PhCH2O), 4.26* (d, J = 6.8 Hz, 0.29H, H-6′′′), 3.96 (d, J = 7.1 Hz, 
0.71H, H-6′′′), 3.88 (s, 2.73H, OCH3), 3.85* (s, 0.87H, OCH3), 3.83 (s, 2.73H, OCH3), 3.77* (s, 
0.87H, OCH3), 3.71 (s, 3H, OCH3), 3.32 – 3.22 (m, 1H, H-1′′′), 2.78* (d, J = 18.3 Hz, 0.29H, H-7′′′A 
(minor)), 2.74 – 2.60 (m, 1.71H, H-7′′′A and H-9a′′′), 2.31* (d, J = 17.4 Hz, 0.29H, H-7′′′B (minor)), 
2.18 – 1.93 (m, 1.71H, H-4′′′A and H-7′′′B), 1.87 – 1.72 (m, 2H, H-2′′′A and H-4′′′B), 1.47 – 1.30 (m, 
2H, H-3′′′), 1.19 – 1.11 (m, 1H, H-2′′′B), 0.88 (s, 6.39H, (CH3)3CSi), 0.87* (s, 2.61H, (CH3)3CSi), 0.05 
(s, 2.13H, CH3Si), 0.03* (s, 0.87H, CH3Si), 0.02 (s, 2.13H, CH3Si), 0.00* (s, 0.87H, CH3Si). 13C 
NMR (125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 166.7 (C-1), 166.6* 
(C-1), 157.0* (C-6′), 156.9 (C-6′), 148.3 (C-4′′), 147.3 (C-5′′), 146.7* (C-5′′), 143.5* (C-3), 143.4 (C-
3), 137.0* (ArC), 136.95 (ArC), 135.0* (C-2′), 134.7 (C-2′), 132.5 (C-2′′), 132.1* (C-2′′), 131.2 (C-
1′), 131.2* (C-4′), 131.0 (C-4′), 130.7 (C-1′′), 130.6* (C-1′), 130.0* (C-1′′), 128.7* (0.58 x ArCH), 
128.6 (1.42 x ArCH), 127.9 (0.71 x ArCH), 127.8* (0.29 x ArCH), 127.7* (C-9′′′), 127.6 (C-3′), 
127.4 (C-9′′′), 127.1* (C-3′), 126.9 (1.42x ArCH), 126.5* (0.58 x ArCH), 125.7 (C-8′′′), 125.2* (C-
8′′′), 117.3 (C-2), 113.7* (C-5′), 113.2 (C-5′), 112.0* (C-6′′), 112.0 (C-6′′), 110.6* (C-3′′), 110.3 (C-
3′′), 72.7 (C-1′′′), 72.5* (C-1′′′), 70.6 (PhCH2O), 69.9* (PhCH2O), 61.7* (C-9a′′′), 61.4 (C-9a′′′), 56.1 
(C-6′′′), 55.9 (OCH3), 55.89* (OCH3), 54.5* (C-6′′′), 51.4 (OCH3), 51.3 (C-4′′′), 50.6* (C-4′′′), 35.1* 
(C-2′′′), 35.0 (C-2′′′), 32.8* (C-7′′′), 32.1 (C-7′′′), 26.0 ((CH3)3CSi), 23.7 (C-3′′′), 23.3 (C-3′′′), 18.2 
((CH3)3CSi), -3.8 (CH3Si), -3.9* (CH3Si), -4.5 (CH3Si). HRMS (ESI): m/z calcd for C40H52NO6Si [M 
+ H]+: 670.3564; found: 670.3581. 
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4.27.2 Synthesis of Methyl (Z)-3-(6-(benzyloxy)-2'-((1R,6S,9aR)-1-((tert-butyldimethylsilyl)oxy)-
1,3,4,6,7,9a-hexahydro-2H-quinolizin-6-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-yl)acrylate (34b) 
Ester 34b was prepared from compound 33b (24.4 mg, 0.0397 mmol) according to the 
General Method for the Still–Gennari Modified Horner-Wadsworth-Emmons Reaction. Purification 
by column chromatography on silica gel eluting with 20:80 EtOAc/hexanes afforded the title 
compound 34b as a pale yellow oil (14.7 mg, 56 %). 1H NMR analysis revealed the presence of two 
biphenyl axis rotamers in a 48:52 ratio. Rf = 0.23 (EtOAc:hexanes = 20:80). IR (neat): νmax 2933, 
2852, 1721, 1599, 1514, 1498, 1250, 1172, 831, 773 cm-1. [𝛼]𝐷
25  + 14 (c 0.92, CHCl3). 1H NMR (500 
MHz, CDCl3): δ 7.83 (td, J = 8.3, 2.3 Hz, 1H, H-4′), 7.38 (d, J = 2.4 Hz, 0.52H, H-2′), 7.35* (d, J = 
2.4 Hz, 0.48H, H-2′), 7.32 – 7.16 (m, 6H, ArH and H-3′′), 6.94 (d, J = 8.7 Hz, 0.52H, H-5′), 6.92* (d, 
J = 8.7 Hz, 0.48H, H-5′), 6.84* (d, J = 12.8 Hz, 0.48H, H-3), 6.83 (d, J = 12.8 Hz, 0.52H, H-3), 6.65* 
(s, 0.48H, H-6′′), 6.62 (s, 0.52H, H-6′′), 5.84* (d, J = 12.8 Hz, 0.48H, H-2), 5.84 (d, J = 12.8 Hz, 
0.52H, H-2), 5.65 – 5.57 (m, 1H, H-8′′), 5.33 (t, J = 12.0 Hz, 1H, H-9′′), 5.16 – 5.02 (m, 2H, 
PhCH2O), 3.90* (s, 1.44H, OCH3), 3.89* (s, 1.44H, OCH3), 3.84 (s, 1.56H, OCH3), 3.83 (s, 1.56H, 
OCH3), 3.74 (s, 1H, H-1′′′), 3.71 (s, 3H, OCH3), 3.32* – 3.28* (m, 0.48H, H-6′′′), 3.20 – 3.15 (s, 
0.52H, H-6′′′), 2.74 – 2.61 (m, 3H, H-4′′′ and H-9a′′′), 2.26 – 1.95 (m, 2H, H-7′′′), 1.88 – 1.55 (m, 2H, 
H-2′′′A (major), H-3′′′A (major) and H-3′′′A (minor)), 1.50 – 1.36 (m, 0.96H, H-2′′′ (minor)), 1.36 – 1.20 
(m, 1H, H-2′′′B (major), H-3′′′B (minor)), 0.91 (s, 9.52H, H-3′′′B (major) and (CH3)3CSi)), 0.01 (s, 6H 
CH3Si). 13C NMR (125 MHz, CDCl3): δ 166.7 (C-1), 157.3* (C-6′), 156.7 (C-6′), 148.9 (C-4′′), 
148.8* (C-4′′), 146.8 (C-5), 146.7* (C-5), 143.5 (C-3), 143.46* (C-3), 136.9* (ArC), 136.87 (ArC), 
136.5 (C-2′′), 135.5* (C-2′′), 134.9 (C-2′), 134.4* (C-2′), 130.9 (C-4′), 130.6* (C-4′), 130.4 (C-1′), 
130.2* (C-1′), 129.8* (C-1′′), 129.3 (C-1′′), 128.8 (C-9′′′), 128.6* (C-9′′′), 128.5* (0.96 x ArCH), 
128.3 (1.04 x ArCH), 127.6* (0.48 x ArCH), 127.57 (0.52 x ArCH), 127.0* (C-3′), 126.9 (C-3′), 
126.7* (0.96 x ArCH), 126.6 (1.04 x ArCH), 125.4* (C-8′′′), 124.9 (C-8′′′), 116.9 (C-2), 116.8* (C-2), 
112.53* (C-6′′), 112.5 (C-6′′), 112.0 (C-5′), 111.8* (C-5′), 109.7 (C-3′′), 109.4 (C-3′′), 70.0 
(PhCH2O), 69.9* (PhCH2O), 69.7* (C-1′′′), 69.69 (C-1′′′), 65.9* (C-9a′′′), 65.7 (C-9a′′′), 59.4 (C-6′′′), 
59.1* (C-6′′′), 55.83 (OCH3), 55.8* (OCH3), 55.7* (OCH3), 55.6 (OCH3), 52.2 (C-4′′′), 51.3 (OCH3), 
35.7 (C-7′′′), 34.5* (C-7′′′), 33.3 (C-2′′′), 33.1* (C-2′′′), 25.8 ((CH3)3CSi), 25.78* ((CH3)3CSi), 21.6* 
(C-3′′′), 21.3 (C-3′′′), 18.2* ((CH3)3CSi), 18.2 ((CH3)3CSi), -4.3 (CH3Si), -4.7 (CH3Si). HRMS (ESI): 
m/z calcd for C40H52NO6Si [M + H]+: 670.3564; found: 670.3595. 
4.28 Synthesis of (1R,6S,9aS)-6-(2'-(Benzyloxy)-5'-((Z)-2-bromovinyl)-4,5-dimethoxy-[1,1'-biphenyl]-
2-yl)-1-((tert-butyldimethylsilyl)oxy)-1,3,4,6,7,9a-hexahydro-2H-quinolizine (35a) 
To a solution of the crude acid 34a (10.6 mg, 16.1 µmol, 1.0 equiv) in MeCN (81 µL) was 
added diphenyl diselenide (0.3 mg, 0.81 µmol, 0.05 equiv) and the mixture was cooled to at -30 °C. 
Next, N-bromosuccinimide (3.5 mg, 19.4 µmol, 1.2 equiv) was added and the reaction mixture was 
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stirred for 2 h. The mixture was dilute with EtOAc (0.8 mL) and washed with water (2 x 2 mL). The 
organic layer was brine, dried (MgSO4), filtered and concentrated in vacuo. The crude product was 
purified by column chromatography on silica gel eluting with 20:80 EtOAc/hexanes to afford the title 
compound 35a as a pale yellow oil (2.0 mg, 18 %). 1H NMR analysis revealed the presence of two 
biphenyl axis rotamers in a 39:61 ratio. Rf = 0.35 (EtOAc:hexanes = 30:70). IR (neat): νmax 3037, 
2927, 2854, 1660, 1513, 1492, 1462, 1250, 1113, 1092, 1016, 834, 774, 734, 696 cm-1. [𝛼]𝐷
25 - 12.3 (c 
0.10, CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 
7.64 (d, J = 2.4 Hz, 0.69H, H-6′′), 7.57 (dd, J = 8.6, 2.4 Hz, 0.69H, H-4′′), 7.55* (dd, J = 8.6, 2.4 Hz, 
0.31H, H-4′′), 7.52* (d, J = 2.3 Hz, 0.31H, H-6′′), 7.33 – 7.16 (m, 5H, ArH), 7.15* (s, 0.31H, H-3′), 
7.11 (s, 0.69H, H-3′), 7.04* (d, J = 8.6 Hz, 0.31H, H-3′′), 7.02 (d, J = 8.0 Hz, 0.69H, H-1′′′), 6.99* (d, 
J = 8.0 Hz, 0.31H, H-1′′′), 6.91* (d, J = 8.6 Hz, 0.31H, H-3′′), 6.81* (s, 0.31H, H-6′), 6.66 (s, 0.69H, 
H-6′), 6.34 (d, J = 8.0 Hz, 0.69H, H-2′′′), 6.32* (d, J = 8.0 Hz, 0.31H, H-2′′′), 6.14 – 6.07 (m, 1H, H-
9), 5.99* – 5.93* (m, 0.31H, H-8), 5.90 – 5.86 (m, 0.69H, H-8), 5.15* (d, J = 12.4 Hz, 0.31H 
PhCHAHBO (minor)), 5.08 – 4.98 (m, 1.69H, PhCHAHBO (minor) and PhCH2O), 4.32* (dd, J = 6.9, 
2.7 Hz, 0.31H, H-6), 3.97 (d, J = 6.9 Hz, 0.69H, H-6), 3.87 (s, 2.07H, OCH3), 3.85* (s, 0.93H, 
OCH3), 3.83 (s, 2.07H, OCH3), 3.78* (s, 0.93H, OCH3), 3.31 – 3.24 (m, 1H, H-1), 2.81 – 2.68 (m, 1H, 
H-7A and H-7A (minor)), 2.65 (d, J = 7.8 Hz, 1H, H-9a), 2.37* – 2.30* (m, 0.31H, H-7B (minor)), 2.19 
– 2.12 (m, 1H, H-4A), 2.11 – 2.04 (m, 0.69H, H-7B), 1.86 – 1.79 (m, 2H, H-2A and H-4B), 1.40 – 1.35 
(m, 2H, H-3), 1.18 – 1.12 (m, 1H, H-2B), 0.88 (d, J = 1.2 Hz, 6.21H, (CH3)3CSi), 0.87* (s, 2.79H, 
(CH3)3CSi), 0.05 (s, 2.07H, CH3Si), 0.03* (s, 0.93H, CH3Si), 0.02 (s, 3H, CH3Si). 13C NMR (125 
MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 155.9* (C-2′′), 155.8 (C-2′′), 
148.3* (C-4′), 148.2 (C-4′), 147.2 (C-5′), 136.9 (ArC), 136.5* (ArC), 132.9* (C-6′′), 132.7 (C-6′′), 
132.4 (C-2′), 131.9* (C-2′), 131.6 (C-1′′′), 131.4* (C-1′′′), 130.6 (C-1′ and C-1′′), 129.6* (C-4′′), 
129.5 (C-4′′), 128.5* (C-5′′ and 0.62 x ArCH), 128.45 (1.38 x ArCH), 127.8* (0.31 x ArCH), 127.7 
(0.69 x ArCH), 127.3 (C-9), 126.8 (1.38x ArCH), 126.4* (0.62 x ArCH), 125.5 (C-8), 125.0* (C-8), 
113.5* (C-6′), 112.8 (C-6′), 112.2* (C-3′′), 112.1 (C-3′′), 110.4* (C-3′), 110.1 (C-3′), 104.8 (C-2′′′), 
72.6 (C-1), 72.2* (C-1), 70.5 (PhCH2O), 69.7* (PhCH2O), 61.6* (C-9a), 61.3 (C-9a), 56.0 (C-6), 55.8 
(OCH3), 54.3* (C-6), 51.3 (C-4), 50.4* (C-4), 35.0* (C-2), 34.8 (C-2), 32.8* (C-7), 32.0 (C-7), 25.9 
((CH3)3CSi), 23.6 (C-3), 18.1 ((CH3)3CSi), -4.0 (CH3Si), -4.7 (CH3Si). HRMS (ESI): m/z calcd for 
C38H49NO4SiBr [M + H]+: 690.2614; found: 690.2648. 
4.29 Synthesis of (1R,6S,9aR)-6-(2'-(Benzyloxy)-5'-((Z)-2-bromovinyl)-4,5-dimethoxy-[1,1'-biphenyl]-
2-yl)-1-((tert-butyldimethylsilyl)oxy)-1,3,4,6,7,9a-hexahydro-2H-quinolizine (35b) 
To a solution of the crude acid 34b (5.0 mg, 7.6 µmol, 1.0 equiv) in MeCN (38 µL) was 
added diphenyl diselenide (0.1 mg, 0.38 µmol, 0.05 equiv) and the mixture was cooled to at -30 °C. 
Next, N-bromosuccinimide (1.5 mg, 8.36 µmol, 1.1 equiv) was added and the reaction mixture was 
stirred for 5 h. The mixture was dilute with EtOAc (2 mL) and washed with water (2 x 5 mL). The 
49 
 
organic layer was brine, dried (MgSO4), filtered and concentrated in vacuo. The crude product was 
purified by column chromatography on silica gel eluting with 10:90 EtOAc/hexanes to afford the title 
compound 35b as a pale yellow oil (1.0 mg, 14 %). 1H NMR analysis revealed the presence of two 
biphenyl axis rotamers in a 48:52 ratio. Rf = 0.34 (EtOAc:hexanes = 15:75). IR (neat): νmax 3029, 
2925, 2852, 1645, 1600, 1515, 1493, 1460, 1251, 1119, 1022, 871, 736, 696 cm-1. [𝛼]𝐷
25  + 19 (c 0.05, 
CHCl3). 1H NMR (500 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 7.66 (d, 
J = 8.5 Hz, 1H, H-4′′), 7.49 (s, 1H, H-6′′), 7.32 – 7.16 (m, 6H, , H-3′ and ArH), 7.00* (d, J = 8.1 Hz, 
0.48H, H-1′′′), 6.99 (d, J = 8.1 Hz, 0.52H, H-1′′′), 6.96 (d, J = 8.7 Hz, 0.52H, H-3′′), 6.94* (d, J = 8.7 
Hz, 0.48H, H-3′′), 6.64* (s, 0.48H, H-6′), 6.63 (s, 0.52H, H-6′), 6.31 (d, J = 8.1 Hz, 1H, H-2′′′), 5.62 
(d, J = 8.5 Hz, 1H, H-8), 5.34 (t, J = 11.5 Hz, 1H, H-9), 5.12 – 5.01 (m, 2H, PhCH2O), 3.91* (s, 
1.44H, OCH3), 3.89* (s, 1.44H, OCH3), 3.83 (s, 3.12H, OCH3), 3.77 – 3.72 (m, 1H, H-1), 3.35 – 3.30 
(m, 0.52H, H-6), 3.24* – 3.18* (m, 0.48H, H-6), 2.77 – 2.60 (m, 3H, H-4 and H-9a), 2.31 – 1.98 (m, 
2H, H-7), 1.88 – 1.28 (m, 4H, H-2 and H-3), 0.91 (s, 9H, (CH3)3CSi)), 0.01 (s, 6H, CH3Si)). 13C NMR 
(125 MHz, the asterisk* denotes the signal of the minor rotamer, CDCl3): δ 156.3* (C-2′′), 155.7 (C-
2′′), 148.9 (C-4′), 148.8* (C-4′), 146.8* (C-5′), 146.7 (C-5′), 137.0 (ArC), 136.97* (ArC), 136.4* (C-
2′), 135.5 (C-2′), 132.9 (C-6′′), 132.6* (C-6′′), 131.6 (C-3′′′), 131.59* (C-3′′′), 130.7 (C-1′′), 130.5* 
(C-1′′), 129.9* (C-1′), 129.5 (C-1′), 129.3 (C-4′′), 129.1* (C-4′′), 128.8 (C-9), 128.5 (1.04 x ArCH), 
128.3* (0.96 x ArCH), 127.6* (0.48 x ArCH), 127.56 (0.52 x ArCH), 127.3 (C-5′′), 127.28* (C-5′′), 
126.6* (0.96 x ArCH), 126.58 (1.04 x ArCH), 125.4* (C-8), 124.9 (C-8), 112.5(C-6′), 112.2 (C-3′′), 
112.1* (C-3′′), 109.7* (C-3′), 109.4 (C-3′), 104.5 (C-2′′′), 104.4* (C-2′′′), 70.0 (PhCH2O), 69.96* 
(PhCH2O), 69.7 (C-1), 65.9 (C-9a), 65.8* (C-9a), 59.3 (C-6), 59.1* (C-6), 55.9 (OCH3), 55.8 (OCH3), 
55.7* (OCH3), 55.65* (OCH3), 33.3* (C-2), 33.1 (C-2), 25.8 ((CH3)3CSi), 21.6* (C-3), 21.3 (C-3), 
18.2 ((CH3)3CSi), -4.3 (CH3Si), -4.7* (CH3Si) (The methylene carbons C-4 and C-7 were not 
detected.). HRMS (ESI): m/z calcd for C38H49NO4SiBr [M + H]+: 690.2614; found: 690.2642. 
4.30 Synthesis of 6-(Benzyloxy)-2'-((4S,9R,9aS)-9-((tert-butyldimethylsilyl)oxy)-2-hydroxyoctahydro-
2H-quinolizin-4-yl)-4',5'-dimethoxy-[1,1'-biphenyl]-3-carbonitrile (37) 
To a solution of the crude acid 32a (30.5 mg, 0.05 mmol) in THF (100 µL) was added 
Hg(NO3)2 (35.9 mg, 0.11 mmol, 2.2 equiv) and water (100 µL).  The mixture was stirred for 5 days at 
room temperature; NaBH4 solution (0.5 M in 3 M NaOH, 110 µL) was added. The mixture was dilute 
with EtOAc (0.5 mL), the solid mercury was allowed to settle, and the organic layer was separated, 
dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by column 
chromatography on silica gel eluting with 40:60 EtOAc/hexanes to afford the title compound 39 as a 
pale yellow oil (1.0 mg, 6%) and desilylated product 24 (3.8 mg, 15%) as a pale yellow oil. 1H NMR 
analysis revealed the presence of two biphenyl axis rotamers in a 49:51 ratio. Rf = 0.51 
(EtOAc:hexanes = 50:50). IR (neat): νmax 3400, 3061, 2921, 2851, 2224, 1601, 1512, 1492, 1461, 
1250, 1119, 1069, 831, 737, 693 cm-1. 1H NMR (500 MHz, the asterisk* denotes the signal of the 
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minor rotamer, CDCl3): 7.61 (d, J = 8.5 Hz, 1H, H-4), 7.39 (s, 1.49H, H-2 and H-3′(minor)), 7.32 – 
7.25 (m, 3.51H, H-3′ (major) and ArH), 7.22* (d, J = 8.2 Hz, 1H, ArH), 7.17 (d, J = 7.9 Hz, 1H, 
ArH), 7.04 (dd, J = 8.5, 3.3 Hz, 1H, H-5), 6.54 (s, 1H, H-6′), 5.16 – 5.09 (m, 1.49H, PhCH2O (minor) 
and PhCHAHBO), 5.07 (d, J = 12.3 Hz, 0.51H, PhCHAHBO), 4.07* (s, 0.49H, H-8′′), 3.98 (s, 0.51H, 
H-8′′), 3.90* (s, 1.47H, OCH3), 3.89* (s, 1.47H, OCH3), 3.84 (s, 3.06H, OCH3), 3.55 – 3.49 (m, 1H, 
H-1′′), 3.16 – 3.10 (m, 1H, H-6′′), 2.66* (d, J = 10.9 Hz, 0.49H, H-4′′A), 2.59 (d, J = 11.7 Hz, 0.51H, 
H-4′′A), 2.37 – 2.27 (m, 1H, H-9a′′), 2.02 – 1.92 (m, 1H, H-9′′A), 1.75 – 1.51 (m, J = 39.2, 13.4 Hz, 
4.49H, H-2′′A, H-3′′A, H-4′′B (minor) and H-7′′), 1.40 – 1.25 (m, 4.51H, H-2′′B, H-3′′B, H-4′′B and H-
9′′B), 0.94 (s, 9H, (CH3)3CSi)), 0.03* (s, 2.94H, CH3Si), 0.02 (s, 3.06H, CH3Si). 13C NMR (125 MHz, 
the asterisk* denotes the signal of the minor rotamer, CDCl3): 159.9* (C-6), 159.3 (C-6), 149.5 (C-4′), 
147.2* (C-5′), 147.0 (C-5′), 136.0 (ArC), 135.7* (C-2), 135.3 (C-2), 133.5 (C-4), 133.4* (C-4), 132.3 
(ArC), 131.9 (ArC), 128.8 (1.02 x ArCH), 128.7* (0.98 x ArCH), 128.3* (ArCH), 128.1 (1.02 x 
ArCH), 127.1* (ArCH), 126.9 (1.02 x ArCH), 119.4 (C≡N), 113.0* (C-5), 112.9 (C-5), 112.4 (C-6′), 
112.2* (C-6′), 109.9* (C-3′), 109.4 (C-3′), 104.2 (C-3), 103.9* (C-3), 70.5* (PhCH2O), 70.4 
(PhCH2O), 69.9 (C-1′′), 65.3* (C-8′′), 65.0 (C-8′′), 59.5* (C-9a′′), 59.0 (C-9a′′), 58.4* (C-6′′), 58.1 (C-
6′′), 56.1 (OCH3), 55.8* (OCH3), 53.3 (C-4′′), 52.6* (C-4′′), 42.8 (C-7′′), 41.2* (C-7′′), 36.3* (C-9′′), 
35.9 (C-9′′), 33.3 (C-2′′), 33.1* (C-2′′), 26.0 ((CH3)3CSi), 20.5 (C-3′′), 18.3 ((CH3)3CSi), -4.1 (CH3Si), 
-4.8* (CH3Si). HRMS (ESI): m/z calcd for C37H49N2O5Si [M + H]+: 629.3405; found: 629.3411. 
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